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ABSTRACT
PATIENT-THERAPIST CONVERGENCE IN ALLIANCE AND SESSION
PROGRESS RATINGS AS PREDICTORS OF OUTCOME IN PSYCHOTHERAPY
FOR GENERALIZED ANXIETY DISORDER
SEPTEMBER 2016
ALICE COYNE, B.A., ALBION COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Michael J. Constantino
The degree to which patients and their therapists align over time on their perceptions of
therapeutic processes and intermediary outcomes has generally been regarded as an
important element of effective psychotherapy; however, few studies have examined
empirically the influence of such dyadic convergences on ultimate treatment outcomes.
This study examined (a) whether early treatment convergences in patient-therapist
alliance and session progress ratings were associated with subsequent worry and distress
reduction (and final posttreatment level) in psychotherapy for generalized anxiety
disorder (GAD), and (b) whether treatment type and the initial (session 1) levels of
perceived alliance and session progress moderated these associations. Data derived from
a clinical trial in which patients with severe GAD were randomly assigned to receive
either 15 sessions of cognitive-behavioral therapy (CBT; n = 43) or 4 sessions of
motivational interviewing (MI) followed by 11 integrative CBT-MI sessions (n = 42).
Patients and therapists rated the alliance and session progress after each session. Patients
rated their worry and distress multiple times throughout treatment. Dyadic multilevel
modeling revealed, as predicted, that alliance convergence over the first half of therapy
iii

was associated with greater subsequent worry (p = .03) and distress (p = .01) reduction.
Additionally, the combination of low initial patient-rated alliance and early divergence
was associated with the worst trajectory for the distress outcome (p = .04). Unexpectedly,
session progress divergence had a near significant association with lower posttreatment
worry (p = .05) and was significantly associated with more accelerated subsequent
distress reduction (p = .03). Additionally, for patients who perceived their initial progress
more positively, whether dyads converged or diverged in early session progress ratings
affected the trajectories (though not the ultimate amount) of distress change (p = .02).
These findings suggest that divergence of early patient-therapist alliance perspectives,
especially when coupled with lower initial patient-rated alliance quality, may be an
important marker for patient nonresponse and therapist responsiveness (e.g., use of
alliance repair strategies). The findings on patient-therapist session progress convergence
are less straightforward, though several possible implications are discussed.
Keywords: Patient-therapist convergence, alliance, session progress, generalized
anxiety disorder, cognitive-behavioral therapy, motivational interviewing
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CHAPTER 1
INTRODUCTION
Social psychological research has demonstrated that convergence, or the process
of two people becoming more similar over time on their perceptions or experiences,
appears to be a general process occurring across different types of close relationships and
at different levels of analysis. For example, relationship partners demonstrate
convergence in their emotions (Anderson & Keltner, 2004; Anderson, Keltner, & John,
2003), attitudes and values (Acitelli et al., 2001), and perceptions of others (Kenny &
Kashy, 1994). The pervasiveness of convergences in close relationships may point to
their adaptive value; similar perceptions and experiences in relationships have been
associated with greater perceived closeness, trust, and relationship satisfaction (Anderson
& Keltner, 2004; Gonzaga, Campos, & Bradbury, 2007). Additionally, the degree of
emotional convergence in couples has predicted whether that couple remained together
six months later (Anderson & Keltner, 2004). This finding also seems to apply to
friendship dyads, as emotional convergence was associated with the intention to maintain
the friendship in the future (Anderson & Keltner, 2004). Thus, one general marker of a
healthy close relationship is that over time individuals tend to converge in their emotions,
perceptions, and attitudes, resulting in more lasting, cohesive, and satisfying relationships
(Anderson & Keltner, 2004).
Inasmuch as psychotherapy is a social exchange tending toward a close
relationship between patient and therapist, convergence may have a bearing on its
success. Although convergence has rarely been studied directly in psychotherapy, the
process of convergence, and its clinical importance, is reflected in the field’s
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longstanding focus on the therapeutic alliance. The alliance is an inherently dyadic
construct reflecting patient-therapist agreement on the goals and tasks of therapy in the
presence of a felt relational bond (Bordin, 1979). Thus, a quality alliance can be seen as
reflecting a high degree of instrumental and emotional attunement. And, consistent with
social psychological research, such attunement is not simply an achieved static state, but
rather an evolving dyadic experience (Bordin, 1979, 1994). Therefore, a quality alliance
would be one in which the patient-therapist dyad worked together in therapy to arrive at,
over time, a more aligned (convergent) understanding of the therapeutic process and
relationship (i.e., goal/task agreement and perceived bondedness). This increase in
instrumental and emotional attunement squares with psychotherapy-specific convergence
theories, which suggest that increases in dyadic attunement over time should promote
treatment success (Pepinsky & Karst, 1964).
Indeed, there is substantial evidence that a quality therapeutic alliance, assessed
from various perspectives, is associated with better treatment outcomes, explaining a
robust 7.5% of outcome variance in the most recent meta-analysis (Horvath, Del Re,
Flückiger, & Symonds, 2011). Although many studies examining the relation between
alliance and outcome have failed to rule out reverse causation (i.e., that a quality alliance
is a byproduct of improvement rather than a predictor of it), some more recent stringent
examinations of the directional alliance-outcome association have found that the alliance
predicts symptom change measured after the alliance, even when controlling for
symptom change measured before the alliance (e.g., Arnow, et al., 2013; Falkenström,
Granström, & Holmqvist, 2014). Such findings suggest that alliance generates symptom
change, rather than merely reflecting a consequence of it. On the whole, the large

2

research base provides compelling evidence for the clinical importance of the patienttherapist alliance (Muran & Barber, 2010). Yet, this research tells us surprisingly little
about the role of the patient-therapist alliance when truly measured at the dyadic level;
that is, there has been a mismatch between the way the alliance is conceptualized and the
predominant way it is measured (Laws et al., 2016).
The vast majority of alliance-outcome studies have assessed the relationship from
one perspective at a time (i.e., patient, therapist, or observer; Elvins & Green, 2008) and
at only one or a few time points (Horvath et al., 2011). This non-dyadic measurement of
the collaborative aspects of the alliance is especially problematic given that actual
agreement between patients and therapists on target problems (at the dyad level) has been
shown to be unrelated to the agreement component of the alliance as rated by patients and
therapists separately (at the individual level; Busseri & Tyler, 2004). This finding
suggests that dyadic agreement may differ from individually-perceived agreement. Thus,
most alliance studies obscure the dyad, failing to provide an accurate test of the influence
of genuine dyadic agreement at the instrumental (perceived goal/task agreement) and
emotional (perceived bondedness) levels. Even fewer studies have examined how both
perspectives change over time (i.e., convergence).
Studies that have measured both alliance perspectives have generally found that
although both are associated with outcome (Horvath et al., 2011), patients’ and therapists’
ratings are only moderately associated with each other (see Tryon, Blackwell, &
Hammel, 2007 for a meta-analytic review). Moreover, variability in patient and therapist
alliance ratings has been shown to be more attributable to the unique patient-therapist
dyad than to the person of the therapist (Marcus, Kashy, & Baldwin, 2009). These
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findings suggest that unique information may be gained by studying the alliance at the
dyad level.
The few studies that have examined the alliance dyadically have done so in a
variety of ways. Some have straightforwardly tested whether similarity in patient and
therapist alliance ratings at one particular point in time (also referred to as attunement or
congruence) is predictive of treatment outcome. For example, in one study of various
psychotherapeutic treatments for various disorders, early similarity between patients and
therapists’ ratings of goal agreement (one alliance element) was associated with early
adaptive change (Long, 2001). Other studies have looked more complexly at alliance
attunement and outcome. For example, in an investigation of diverse treatments for
diverse disorders, the interaction between early alliance level and early patient-therapist
alliance attunement predicted outcome; for dyads with high quality alliances (as rated
independently by patients and therapists), greater similarity/attunement in patienttherapist alliance ratings was related to greater symptom reduction (Marmarosh &
Kivlighan, 2012). This result suggests that outcome may be most positively influenced
when both partners independently rate the alliance as high and agree on this rating
dyadically.
Still other studies have examined changes in the similarity of patient and therapist
alliance ratings over the course of therapy (i.e., dyadic convergence). In a naturalistic
study of 270 dyads in which patients with a variety of problems were primarily treated
with psychodynamic therapy, similarity in patient and therapist alliance ratings increased
significantly over time (greater convergence); however, the authors did not report the
relation between convergence and outcome (Hersoug, Høglend, Monsen, & Havik,
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2001). To my knowledge, only one study has used dyadic analyses to examine patienttherapist alliance rating convergence over treatment and its association with ultimate
treatment outcome. Specifically, Laws et al. (2016) examined this question with patients
receiving either cognitive-behavioral analysis system of psychotherapy (CBASP) or brief
supportive psychotherapy (BSP) for chronic depression. Patient-therapist alliance ratings
evidenced increased convergence over time, which was associated with a steeper
reduction in depressive symptoms and lower depression level at termination.
Additionally, patient-therapist alliance convergence significantly predicted depression
level at follow-up, controlling for patient-rated alliance level and depression level at the
end of treatment. (This analysis preserved temporal precedence between the convergence
variable and the outcome variable, rendering it more likely that convergence preceded
subsequent improvement rather than the other way around.) The Laws et al. findings
provided initial evidence that patients and therapists do tend to converge in their alliance
perceptions as therapy progresses, and that this convergence is associated with favorable
patient outcome. Of course, the association between convergence in patient-therapist
alliance ratings and outcome requires replication. In addition, Laws et al.’s findings must
be considered preliminary in that convergence was only significantly associated with
lower pharmacotherapist-rated depression scores; it was not associated with outcome
when depression was assessed by raters blind to treatment condition.
To date, research on dyadic attunement in psychotherapy has largely focused on
the alliance. Yet, consistent with general attunement/convergence theories, it seems likely
that the importance of patient-therapist similarity is not limited to agreement on
perceptions of alliance quality, but likely also generalizes to agreement on concrete
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extensions of the alliance (such as aligned perspectives on the effectiveness of the tasks
in which the patient and therapist are engaged to accomplish the agreed upon therapy
goals). Presumably, then, it would also be important for patients and their therapists to
align on ratings of session-by-session progress, or helpfulness.
The link between session progress, or the general helpfulness of a session (as
rated from one perspective), and ultimate treatment outcome has been well established.
Unsurprisingly, higher patient-perceived session progress at a given time point has been
related to better posttreatment outcome in varied treatments for varied conditions
(Bernard, Schwartz, Oclatis & Stiner, 1980; Kolden, 1996; Mallinckrodt, 1993; Watson
& Greenberg, 1996). Additionally, session evaluations have been associated with alliance
quality (Kivlighan, Marmarosh, & Hilsenroth, 2014; Mallinckrodt, 1993), which, as
noted, is a consistent predictor of outcome (Horvath et al., 2011). Thus, given its direct
relation with adaptive processes and outcomes, it makes sense to examine further session
progress as a dyadic construct; like the alliance construct, it may be that patient-therapist
attunement (at a given time) or convergence (across time) on this variable explains
additional, and possibly more, outcome variance than progress rated by only one dyad
member at one point in time. To my knowledge, though, no research has examined
whether alignment between patient-therapist views of session progress changes over
therapy, and if such a change (convergence/divergence) is associated with outcome (as
suggested by convergence theories). However, some parallels can be drawn to one study
that found that patient-therapist convergence in recall of important session events
increased significantly over time, and that such increased convergence was associated
with greater reduction in interpersonal problems (Kivlighan & Arthur, 2000).
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To the extent that patient-therapist perceptual convergence has a bearing on
treatment process and outcome, it may be important to consider clinical contexts in which
it is especially salient. It is plausible that patient-therapist convergence may be
particularly important for patients who are more resistant to or ambivalent about change,
thereby creating a greater possibility for misattunement to occur between patients and
their therapists. For example, patients with generalized anxiety disorder (GAD) are
characterized by high change ambivalence and higher rates of resistance compared to
other disorders (Borkovec & Roemer, 1995; Westra, 2004). Some researchers have
suggested that such resistance can be conceptualized as limited collaboration between
patients and therapists (i.e., misattunement or low convergence; Aviram & Westra,
2011); moreover, these same authors found that early patient resistance predicted poorer
treatment engagement and outcomes among patients with GAD. Thus, it seems highly
relevant to examine the process of dyadic convergence in the context of treatments for
GAD.
Thus, the goals of present study were to examine whether patient-therapist dyads
exhibit convergence in their ratings of alliance and session progress over time, and
whether such convergences were associated with treatment outcome in psychotherapy for
GAD. The context for the study included patients who received either cognitivebehavioral therapy (CBT) or CBT integrated with motivational interviewing (MI), an
intervention that focuses on reducing change ambivalence/treatment resistance and
increasing intrinsic motivation for change (Miller & Rollnick, 2002). Consistent with
previous research (Hersoug et al., 2001; Laws et al., 2016), I predicted that patients and
their therapist would rate their alliance and session progress more similarly as their
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relationship progressed. Also consistent with the limited extant literature (Laws et al.,
2016), I predicted that greater early treatment convergence in patient-therapist alliance
and session progress ratings would be associated with more positive subsequent
outcomes (i.e., worry and global distress reduction). I examined early alliance and session
progress convergence in the prediction of subsequent worry and distress in order to
preserve temporal precedence and have greater faith that convergence preceded
subsequent improvement rather than the other way around.
Additionally, I examined whether treatment condition (CBT vs. MI-CBT) or
average initial levels (of the alliance and session progress) moderated the relation
between the early convergence variables and the subsequent outcomes. Given that no
prior research has examined moderators of convergence-outcome findings, these analyses
were exploratory. Different interactive effects were conceivable. Because of MI’s focus
on increasing collaboration and reducing resistance (Aviram & Westra, 2011), it is
possible that the expected positive associations between the convergence variables and
outcomes could be stronger in MI-CBT vs. CBT only patients; that is, when the treatment
explicitly focuses on collaboration, actually experiencing convergent perceptions of the
relationship and progress over time may have stronger effects on subsequent outcome.
Alternatively, it is plausible that convergence will be most important for outcome when a
treatment does not explicitly address ambivalence; that is, in CBT, it could be that lack of
convergence (which, as noted, could be conceived as a type of resistance) and the
absence of the MI approach to address such lack could be particularly disruptive to
treatment effectiveness. Again, this moderator analysis was exploratory, and aimed at
clarifying these rival possibilities. Finally, based on Marmarosh and Kivlighan’s (2012)
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finding that alliance level moderated the relation between similarity in patient-therapist
alliance ratings (at one point in time) and symptom change, it could be that for dyads in
the present study with higher early alliance quality, greater early convergence in patienttherapist alliance ratings would relate to greater subsequent worry and distress reduction.
I explored this interaction too.
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CHAPTER 2
METHOD
2.1 Dataset Overview
Data for the present study were derived from a randomized controlled trial
comparing the efficacy of 15 CBT sessions or 4 MI sessions followed by 11 integrative
MI-CBT sessions for GAD (Westra, Constantino, & Antony, 2016). The trial involved
two sites, York University and Ryerson University, with both treatments conducted at
each site. Participants were matched between conditions for treatment outcome
expectations. The few baseline variables for which the groups differed by chance (see
below) were accounted for in the primary outcome analyses. Briefly, the treatment groups
did not differ in their rates of change on worry or global distress across the acute
treatment phase. However, MI-CBT patients evidenced significantly more improvement
than CBT patients on these primary outcome variables from posttreatment through 1-year
follow-up. Also across the follow-up period, patients in the MI-CBT group demonstrated
greater clinically significant change in terms of assessor-rated diagnostic status, as well
as reliable and clinically relevant reduction in worry and global distress (see Westra et al.,
2016). Attrition was fairly low across both treatment conditions. During the active
treatment phase, there were 10 dropouts in CBT (23%) and 4 in MI-CBT (10%). As
noted, the present novel analyses of these archived trial data focused on the prediction of
the self-reported continuous outcomes (worry, global distress) from the convergence
variables (alliance, session progress), while also addressing treatment condition and early
level of alliance and session progress as possible moderators of the convergence-outcome
relations.
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2.2 Participants
2.2.1 Patients. Eighty-five participants (age 16 or older) meeting Diagnostic and
Statistical Manual of Mental Disorders – Fourth Edition, Text Revision (DSM-IV-TR;
American Psychiatric Association, 2000) criteria for principal GAD were randomly
assigned to treatment condition (ns = 43 and 42 for CBT and MI-CBT, respectively).
Only those with high worry severity (a score of ≥ 68 on the Penn State Worry
Questionnaire [PSWQ]; Meyer, Miller, Metzger, & Borkovec, 1990) were included in the
study, as baseline severity differentiated patients who did and did not respond favorably
to the addition of a MI pretreatment in a pilot study (Westra, Arkowitz, & Dozois, 2009)
prior to the present trial. In order to increase external validity, participants with most
comorbid diagnoses were accepted in the trial (81% had at least one comorbid condition).
Patients on antidepressant medication were also included provided that their dose had
been stable for 3 months prior to the study and they agreed to remain on their current
dose throughout the study (n = 20). Exclusion criterion included (a) engaging in any
concomitant psychotherapy, (b) benzodiazepine use, and (c) meeting criteria for any of
the following co-occurring conditions: psychotic or bipolar disorders, substance
dependence within the last 6 months, cognitive impairment, or severe suicidal ideation.
Table 1 presents descriptive statistics for the entire sample by treatment condition.
The treatment groups did not differ significantly at baseline on measures of self-reported
symptom severity (i.e., worry, global distress) or on any demographic variables other
than gender; the CBT condition had significantly more women (n = 41 vs. n = 34) and
fewer men (n = 2 vs. n = 8) than the MI-CBT condition, χ2 (1) = 4.24, p = .039. The two
conditions also differed on medication status; significantly more patients in CBT (n = 14)
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than MI-CBT (n = 6) were on antidepressant medication, χ2 (1) = 3.94, p = .047.
Additionally, patients in the CBT condition reported significantly higher motivation at
baseline than patients in the MI-CBT condition as assessed by the 12-item Change
Questionnaire (CQ; Miller & Johnson, 2008), t(83) = -2.55, p = .013.1
2.2.2 Therapists. Twenty-two trainees self-selected into condition, providing
either CBT or MI-CBT. This nesting within condition was designed to control for
allegiance and crossover effects. There were 13 female therapists in the CBT alone
condition (12 doctoral candidates in clinical psychology and one postdoctoral
psychologist) who saw between 1 and 7 cases each (median of 5). These therapists had no
formal training in MI, and 92% endorsed cognitive-behavioral as their primary
orientation. There were 9 female therapists in the MI-CBT condition (eight doctoral
candidates in clinical psychology and one postdoctoral psychologist) who saw between 3
and 14 cases each (median of 5). Of these therapists, 56% endorsed integrative as their
primary orientation, 22% endorsed client-centered, and 22% endorsed cognitivebehavioral. Across both treatment conditions, therapists were on average 28.54 years old
(SD = 2.77 years), and they averaged 276.08 hours of clinical experience (SD = 371.62
hours). The therapists did not significantly differ between conditions in terms of age or
amount of clinical experience.
For both conditions, therapists were trained extensively through a combination of
workshops and pilot case feedback. The trial principal investigator, an expert in MI and
CBT, conducted training and case supervision for the MI-CBT therapists. A trial co-

1

The CQ is not a variable per se in the present study; rather, given its known influence on the outcome
variables of worry and global distress (Westra et al., 2016), its effects were residualized out of the outcome
variables (see results section below).
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investigator, an expert in CBT, together with a postdoctoral fellow specializing in CBT
(under the co-investigator’s supervision) conducted CBT training (for both groups) and
supervised the CBT alone therapists. Therapists were required to show competent
treatment delivery (based on supervisor assessment after repeated video review of
therapy sessions and supervisor completion of the relevant treatment competence
measures) with at least one pilot patient prior to the start of the trial in order to be deemed
proficient. Supervision of study cases consisted of supervisor video review and weekly
individual supervision meetings.
2.3 Treatments
2.3.1 CBT. The CBT condition consisted of 15 weekly (50 min) sessions and was
delivered according to Barlow and colleagues’ CBT for GAD manuals (e.g., Coté &
Barlow, 1992; Craske & Barlow, 2006; Zinbarg, Craske, & Barlow, 2006). This
treatment, which has well-established efficacy (Borkovec, Newman, Pincus, & Lytle,
2002), addresses worry and other features of anxiety with both cognitive (e.g., selfmonitoring of thoughts, challenging distorted cognitions) and behavioral (e.g., relaxation
training, worry exposure) techniques. Strategies for managing resistance were
manualized for this study based on recommendations made by cognitive therapy experts
for addressing homework noncompliance and other treatment challenges (e.g., Beck,
2005). These techniques differed significantly from techniques for managing resistance in
MI (described below) in that therapists were instructed to respond in a much more
directive manner. For example, CBT therapists were encouraged to challenge resistance
explicitly, revise cognitive distortions that are thought to underlie resistance, actively
problem solve obstacles to patient compliance, and provide psychoeducation.
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2.3.2 MI-CBT. The MI-CBT condition consisted first of 4 weekly (50 min)
sessions of “pure” MI based on Miller and Rollnick’s (2002) MI manual adapted for
anxiety (Westra, Arkowitz, & Dozois, 2009; Westra & Dozois, 2003, 2006). MI focuses
on reducing ambivalence about worry through therapists’ expression of empathy and
validation, “rolling with resistance,” and enhancing self-efficacy. MI is a person-centered
therapy that embraces core values, such as patient autonomy, empathy, collaboration, and
evocation. After these 4 initial MI-only sessions, patients in this condition received 11
weekly (50 min) sessions of CBT for GAD based on the same manualized protocol used
in the CBT only condition. However, in addition to providing traditional CBT for GAD,
therapists in this condition were trained to shift back into MI to address moments of
patient resistance. Methods for responding to resistance differed substantially from the
CBT condition. Most notably, MI therapists were encouraged to resist challenging or
confronting resistance directly, and instead were instructed to validate resistance as an
expression of understandable ambivalence about change. Working from a place of
empathy and understanding of the patient’s perspective, therapists attempted to evoke
patients’ internal motivation for change through techniques such as siding with the
resistance and using open-ended questions to elicit arguments for change from patients
themselves.
2.3.3 Relapse prevention. Given high relapse rates for patients with GAD
(Rodriguez et al., 2006), a relapse prevention component was added to both treatments.
This manual was adapted from Whiteside et al.’s (2007) relapse prevention program for
GAD; it involves teaching patients to recognize and manage cognitive worry cues and to
create and practice relapse prevention plans.
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2.3.4 Therapist protocol delivery. Discriminant validity for the treatment
conditions was calculated using a randomly selected subset of 20% of sessions for each
therapist in each condition (sampled from different therapy phases). As Westra et al.
(2016) reported, therapist protocol delivery, as rated by trained observers, was
appropriately different between conditions on key components of MI and CBT.
Therapists in the MI-CBT condition showed greater adherence to MI techniques on the
Motivational Interviewing Treatment Integrity Code (MITI; Moyers, Martin, Manuel,
Hendrickson, & Miller, 2005) compared to therapists in the CBT condition. MI-CBT
therapists evidenced higher MI spirit (effect sizes ranged from d = 2.18, 95% CI: 1.622.69 to d = 3.09, 95% CI: 2.43-3.68) and empathy (effect sizes ranged from d = 2.64,
95% CI: 2.03-3.19 to d = 3.22, 95% CI: 2.55-3.83) compared to CBT therapists.
Similarly, therapists in the CBT alone condition showed higher competence in delivery
“pure” CBT techniques as per the Cognitive Therapy Rating Scale (CTRS; Young &
Beck, 1980) than therapists in the MI-CBT group both early (d = 2.57, 95% CI: 1.973.12) and late (d = 0.87, 95% CI: 0.41-1.30) in therapy. That CBT competence scores
were lower in MI-CBT is attributable to a measurement artifact. As noted, the CTRS
assesses “pure” CBT competence and was not designed to accommodate deviations from
it, such as those necessitated in the purposefully integrated treatment. Such MI
deviations, while reflecting fidelity to the integrative MI-CBT approach, also represented
substantive moments of departure from straight CBT, which would produce lower CTRS
scores from blind observers.
2.4 Measures
2.4.1 Outcome Variables.
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2.4.1.1 Worry. To assess worry, the cardinal feature of GAD, patients completed
the PSWQ (Meyer et al., 1990; see Appendix A), a widely used 16-item questionnaire.
The 5-point scale ranges from 1 to 5, with higher scores reflecting more severe worry
(range = 16 to 80). The PSWQ has shown high internal consistency and reliability, as
well as convergent and discriminant validity (Brown, Antony, & Barlow, 1992; Meyer et
al., 1990). In the present study, the PSWQ demonstrated excellent internal consistency
(Cronbach’s alpha) throughout treatment (average α = .95).
2.4.1.2 Global distress. To assess global distress, patients completed the
Depression Anxiety Stress Scales (DASS; Lovibond & Lovibond, 1995; see Appendix
B), a widely used 21-item questionnaire recommended for inclusion in the assessment of
GAD given that it may be a better measure of the tension and persistent arousal
characteristic of GAD than other commonly used measures of somatic arousal (e.g.,
Campbell & Brown, 2002). The 4-point scale ranges from 0 to 3, with higher total scores
reflecting more severe distress (range = 0 to 63). Subscale scores for depression, anxiety,
and stress can be calculated (7 items per scale; score range 0 to 21). The DASS
demonstrates good reliability and validity, and is a better discriminator between anxiety
and depression than many other commonly used measures (Antony, Bieling, Cox, Enns,
& Swinson, 1998; Lovibond & Lovibond, 1995). The factor structure of the measure has
been replicated in non-clinical (Lovibond & Lovibond, 1995) and clinical (Brown,
Chorpita, Korotitscw, & Barlow, 1997) samples. In the present study, the DASS total
score demonstrated excellent internal consistency (Cronbach’s alpha) throughout
treatment (average α = .92). As my interest was in global distress as an outcome variable,
I used the total score in my analyses.
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2.4.2 Predictor and Moderator Variables.
2.4.2.1 Alliance. To assess the quality of the therapeutic alliance, patients
and therapists completed their respective versions of the Working Alliance InventoryShort Form (WAI-S; Horvath & Greenberg, 1989; Tracey & Kokotovic, 1989; see
Appendices C and D), a widely used 12-item measure based on Bordin’s (1979)
conceptualization of the alliance as consisting of patient-therapist agreement on treatment
goals, agreement on treatment tasks, and an affective bond. The 7-point scale ranges from
1 to 7, with higher total scores reflecting a better alliance (range of 12 to 84). The WAI is
well validated, with good internal consistency and strong evidence of convergent,
discriminant, and predictive validity (Elvins & Green, 2008). In the present study, the
WAI-S total score demonstrated excellent internal consistency (Cronbach’s alpha)
throughout treatment for both the patient (average α = .85) and therapist (average α = .87)
versions. As is typical for the WAI-S, the total score and the subscales were highly
intercorrelated (rs = .56 to .93; all ps < .001); thus, I used only the total score in the
present analyses.
To assess patient and therapist convergence in perceptions of alliance quality
across therapy (the dyadic level predictor variable), I estimated the differences between
patients’ and therapists’ alliance ratings at each session (starting at session 2) using a
difference score model (Lyons & Sayer, 2005; see results section below for further
details). Also, both patient- and therapist-rated initial alliance levels (at session 1) were
examined as moderators in this study.
2.4.2.2 Session progress. To assess session progress, patients and therapists
completed their respective versions of the Session Progress Scale (SPS; Kolden, 1991;
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1993a; 1993b; 1996; see Appendices E and F), a brief 4-item questionnaire that assesses
the overall impact or helpfulness of an individual therapy session. The SPS is derived
from a more comprehensive measure of therapeutic progress, the Therapist Session
Report (TSR; Orlinsky & Howard, 1966; 1986). Previous research has found that the 4
items can be aggregated to create a total score, which represents the overall helpfulness
of a session. Total SPS scores can range from 4 to 25, with lower scores indicating
greater session progress (note that for 1 item, the scale range is from 1 to 7, whereas for
the other 3 items it is 1 to 6). For the present study, I transformed all 4 items to range
from 1 to 7, resulting in a total score that can range from 4 to 28. The SPS has shown
high internal consistency (Kolden, 1991) and strong test-retest reliability (Kolden &
Howard, 1992). Additionally, both the SPS and the TSR demonstrate predictive validity
in that they have related to psychotherapy outcome (Kolden, 1991, 1993a; Kolden &
Howard, 1992). In the present study, the SPS total score demonstrated good internal
consistency (Cronbach’s alpha) throughout treatment for both the patient (average α =
.82) and therapist (average α = .75) versions.
To assess patient and therapist convergence in perceptions of session progress
across time (the dyadic level predictor variable), I estimated the differences between
patients’ and therapists’ session progress ratings at each session using a difference score
model (Lyons & Sayer, 2005; see results section below for further details). Also, both
patient- and therapist-rated session progress levels (at session 1) were examined as
moderators in this study.
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2.5 Procedure
Trial participants responded to community advertisements posted in the greater
Toronto area. After responding, potential participants were phone screened. If eligible, a
trained graduate assessor administered the Structured Clinical Interview for DSM-IV-TR
Axis I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams, 1996) to consenting
participants to determine diagnostic eligibility and assess other clinical features. Eligible
patients were then randomized to treatment across the two sites. The randomization
protocol was administered at a neutral third site by a co-investigator uninvolved in site
procedures and therapist training, and blind to patient clinical features (other than the
matching variables of outcome expectation and worry severity). The PSWQ was
administered at baseline, after every session, and at posttreatment. The DASS was
administered at baseline, after sessions 6, 10, and 14, and at posttreatment. Both the
therapist and patient versions of the WAI-S and SPS were administered after every
session. The institutional review boards at the two data collection sites approved the trial.
2.6 Data Analytic Plan
For my data analyses, I used the hierarchical linear modeling program (HLM7;
Raudenbush, Bryk, & Congdon, 2011) because of its ability to statistically control for
both the correlation between each dyad’s alliance and session progress scores and the
correlation among the measurements of each construct over time. Moreover, because
HLM takes into account information from all individuals in the sample when calculating
parameter estimates, it is robust in handling missing data at level-1 (i.e., the repeated
measures over time). Thus, HLM mimics a modified intention-to-treat approach,
retaining patients in any longitudinal analysis who had at least one score on a measure
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administered more than one time. Effect sizes were calculated by evaluating the
additional percent variance explained with the addition of predictors (a pseudo r2). My
primary data analytic plan consisted of three main steps that are described sequentially
throughout the results section.
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CHAPTER 3
RESULTS
3.1 Creating the Convergence/Divergence Predictor Variables
The first step for generating the main predictor variables of patient-therapist
convergence in alliance and session progress over time was to create discrepancy scores
representing the gap or difference between patients’ and their therapists’ ratings of the
alliance/session progress at each session. To do this, I created a discrepancy indicator
variable, which was then used as the sole predictor in my discrepancy models (described
in detail below). In short, this variable was coded therapists = 0.5 and patients = -0.5 to
ensure that a 1-unit change in this variable would represent the gap or difference between
patients’ and their therapists’ ratings of the alliance/session progress at each session (i.e.,
the slope), and that each model’s intercept would reflect the dyad-level average (i.e., the
expected value of alliance/session progress when patient-therapist discrepancy is equal to
zero). Additionally, to address the issue of limited information on which the model can
generate discrepancy (i.e., only two perspectives through which the model can fit a line),
and to avoid model identification problems, three alliance measurements (i.e., the Goals,
Tasks, and Bond subscales of the WAI) and each of the four SPS items were used for
each dyad member at each measurement session (Cano, Johansen, & Franz, 2005). To
generate these dyad discrepancy scores, I fit 2-level difference score models. To give one
example, depicted below is the model equation used to estimate the alliance session 2
dyad average and discrepancy (the session progress models were identical in structure).
Level 1
WAIij = β1j(S2 WAI average) + β2j(S2 WAI discrepancy indicator) + rij
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Level 2
β1 = γ10 + u1
β2 = γ20 + u2
At level 1, WAIij represents the alliance score i (i = 1 ... 6 parallel scores per
dyad) for dyad j at a given session (in this case, session 2), which was predicted from
each dyad’s average alliance level (β1) and the discrepancy between each dyad member’s
scores (β2). At level 2, these coefficients (i.e., the dyad-level averages and discrepancy
scores) dropped down to be predicted by the average alliance level (γ10) and average
alliance discrepancy score (γ20) for all dyads in the sample. Random effects at level 2 (u1
and u2) allowed each dyad’s alliance averages and discrepancies to vary from the
estimated sample averages. This model was repeated for each session from 2 through 8
and for even numbered sessions from 10 through 14 (i.e., sessions 2, 3, 4, 5, 6, 7, 8, 10,
12, and 14 were estimated).
Post-estimation coefficients (in HLM, Empirical Bayes or EB estimates)
representing the estimated discrepancy score for each patient-therapist dyad at each
session were output from each model’s HLM level 2 residual file. These HLM derived
EB estimates were then used as the outcome variable in our models testing change in
alliance and session progress similarity/discrepancy over time (i.e.,
convergence/divergence).
3.2 Examining Patient-Therapist Alliance Convergence
3.2.1 Descriptive evidence of alliance convergence. The mean WAI discrepancy
scores (absolute values) for patients and therapists at each session are presented in Figure
1. The mean discrepancies between patient and therapist ratings of the alliance were
largest early in treatment (M discrepancy for session 1 = 12.78, SD = 8.62) and smaller
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later in treatment (M discrepancy for session 14 = 9.12, SD = 7.19), suggesting that, on
average, patients’ and therapists’ alliance ratings became more similar over time,
reflecting a pattern of convergence. Moreover, patient-therapist convergence (i.e.,
decrease in discrepancy) appeared steepest during the first half of treatment and seemed
to level off during the second half of treatment.
3.2.2 Estimating alliance discrepancies at each session. The series of 2-level
difference score models (described above) indicated significant discrepancy, on average,
and significant variability around the average discrepancy in patient-therapist alliance
ratings at each session. Empirical Bayes (EB) discrepancy estimates were output from
each model’s HLM level-2 residual file to be used as the outcome variable in the models
testing change in alliance similarity/discrepancy over time (see below).
3.2.3 Estimating alliance discrepancy change over time (i.e.,
convergence/divergence). Prior to fitting our convergence models (i.e., change in
alliance discrepancy), the EB discrepancy scores required transformation. Given the
coding of the discrepancy indicator, dyads in which patients rated the alliance higher than
their therapist received a negative discrepancy score, while dyads in which the therapist
had a higher alliance rating received a positive discrepancy score. Although on average
patients’ alliance ratings were higher than therapists’ ratings at each session, there were
33 dyads for which the therapists rated the alliance higher at one or more sessions
(meaning that for 52 dyads, the patient rated the alliance higher at every session).
Additionally, there were 27 dyads whose discrepancy scores changed from positive to
negative across time (e.g., a patient rated the alliance higher at session 2 and his/her
therapist rated it higher at session 4), rendering it impossible to meaningfully model the
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rate of change in discrepancy for these dyads. As the primary question of this study was
to test for convergence/divergence in patient-therapist alliance ratings (i.e.,
increases/decreases in dyad-level discrepancy over time), I used the absolute value of the
HLM-derived EB discrepancies obtained for each measurement occasion to address the
problem of changing signs (Laws et al., 2016). Because this transformation resulted in
positively skewed distributions, I performed a square root transformation to correct this
skew.
These square root-transformed (absolute value) EB discrepancy scores for
sessions 2, 4, 6, 8, 10, 12, and 14 were used as the outcome in a model that tested alliance
similarity change across treatment. In this model, time was rescaled to capture the total
change over the entire therapeutic period (Bolger & Laurenceau, 2013); that is, the value
of the first session (session 2) was set to 0, and the value of the final session (session 14)
was set to 1, with the intervening weeks spaced equally across the 0 to 1 interval. Thus,
the linear slope parameter represented change in discrepancy across the entire
psychotherapy period for the average dyad.
Results indicated that alliance discrepancy significantly decreased over the course
of psychotherapy (see Table 2, column 1). Specifically, the average alliance discrepancy
at session 2 was estimated as 1.73 (p < .001), which decreased significantly by the end of
psychotherapy (γ10 = -.14, p = .04). Although most dyads showed a pattern of increasing
similarity in alliance ratings (i.e., convergence), there was significant variability in
discrepancy change; in fact, some dyads (n = 17) became more discrepant (i.e., a pattern
of divergence) in their alliance ratings across therapy. Figure 2 displays the rate of
change in discrepancy across treatment on average (Panel A) and the variability around

24

the average (Panel B). Next, based on descriptive evidence suggesting that convergence
appeared steepest early in treatment and leveled off later in treatment, I tested a quadratic
model of alliance convergence/divergence across treatment (see Table 2, column 2);
results indicated that there was no significant curvilinear pattern to alliance discrepancy
change, on average (γ20 = .09, p = .61), no significant between-dyad variability in the rate
of acceleration in alliance discrepancy change across treatment (τ22 = 0.17, p > .50), and
the quadratic model was not a better fit to the data than the linear model, χ2(4) = 2.77, p >
.5.
To test for alliance similarity change across the first half of treatment, the
aforementioned model was repeated using the transformed EB discrepancy scores for
sessions 2 through 8 as the outcome, with time rescaled to represent change across the
first half of psychotherapy. (Thus, the linear change coefficient in this model represented
the average change in alliance discrepancy across the first half of treatment.) See Table 2,
column 3 for the results, which indicated that alliance discrepancy at session 2 was
estimated as γ00 = 1.78 (p < .001), which decreased significantly by session 8 (γ10 = -.14,
p = .01). Similar to convergence/divergence patterns across the entire psychotherapy
period, although most dyads also showed a pattern of increasing similarity in alliance
ratings (i.e., convergence) across the first half of treatment, there was marginally
significant variability in discrepancy change; although all dyads became less discrepant
(i.e., convergent) in their alliance ratings across the first half of therapy, dyads varied in
the amount of convergence. Figure 3 displays the rate of change in discrepancy across the
first half of treatment on average (Panel A) and the variability around that average (Panel
B). Again, based on a visual inspection of the data, I tested a quadratic model of early
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alliance convergence/divergence (see Table 2, column 4); results indicated that there was
no significant curvilinear pattern to early alliance discrepancy change (γ20 = -.01, p =
.94), no significant variability in the rate of acceleration in alliance discrepancy change
(τ22 = 0.20, p = .45), and the quadratic model was not a better fit to the data than the linear
model, χ2(4) = 1.21, p > .5. From the aforementioned linear model (i.e., early linear
change in alliance discrepancy), EB coefficients of each dyad’s estimated change in
discrepancy were output for use as predictors in the final analyses.
Additionally, due to additional inherent nesting in the data (i.e., multiple patients
nested within a single therapist), I ran an unconditional 3-level model to examine the
amount of variability in early alliance convergence/divergence that was accounted for by
the therapist. At level-1, the average discrepancy at session 2 and change in alliance
discrepancy was modeled for patient j at time i seen by therapist k. At level-2, these
averages and discrepancies dropped down to be predicted by the average alliance
discrepancy at session 2 for therapist k and the average rate of change in discrepancy for
therapist k. Random effects at level-2 allowed each patient to vary around their
therapist’s average intercept and slope. At level-3, therapists’ alliance discrepancies at
session 2 and their average rate of change in alliance discrepancy across their caseloads
were predicted by the average session 2 alliance discrepancy and average rate of change
in discrepancy across all of the therapists in the sample. Random effects at level-3
allowed each therapist to vary around the average therapist’s intercept and slope.
Level-1 Model
WAIijk = π0jk + π1jk*(TIMEijk) + eijk
Level-2 Model
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π0jk = β00k + r0jk
π1jk = β10k + r1jk
Level-3 Model
β00k = γ000 + u00k
β10k = γ100 + u10k
Results of this model (see Table 3) indicated that the average therapist alliance
discrepancy at session 2 was estimated as γ000 = 1.75 (p < .001), which decreased
significantly by session 8 (γ100 = -.02, p = .02). Additionally, level-2 random effects
indicated that there was significant within-therapist variability (i.e., between-patients
within a therapist’s caseload) from their own average rate of change in alliance
discrepancy (p = .02), but an examination of the level-3 random effects indicated that
there was no significant between-therapist variability in the rate change in alliance
discrepancy (p > .5). From this model, I calculated an intraclass correlation (ICC) to
determine the variability in session 2 discrepancies (intercept) and rates of change in
discrepancy across the first half of treatment (slope) that was accounted for by the
therapist. Unsurprisingly, approximately 51.94% of the variability in the dyad-level
discrepancy scores was due to the therapist. However, only 4.96% of the variability in the
rate of change in alliance discrepancy over time (slope) was due to therapists, suggesting
that about 95% of the variability in these discrepancy slopes was unique to each dyad. In
other words, even though each therapist saw multiple patients, the correlation between
two patients’ rates of change in discrepancy who were seen by the same therapist was
only about .05. Thus, I retained the EB coefficients of each dyad’s estimated change in
discrepancy from the 2-level model to preserve as much variability in these slopes as
possible for their use as predictors in our subsequent analyses. Additionally, the 2-level
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model had a much higher reliability estimate compared to the 3-level model, suggesting
that the EB coefficients from this model would make more reliable predictors.
3.3 Testing Early Alliance Convergence as a Predictor of Worry and General
Distress
Prior to testing the primary alliance research questions, I examined descriptive
statistics and intercorrelations between all relevant predictors/moderators (i.e., early
alliance convergence/divergence, patient- and therapist-rated session 1 alliance, and
treatment condition) and the baseline covariates of worry and distress (see Table 4). All
of the variables appeared relatively normally distributed (skewness values ranged from 0.37 to .18). Intercorrelations between predictors were low to moderate (rs range from .14 to .36), suggesting no problematic collinearity.
I next tested whether rate of change in alliance discrepancy from session 2
through 8 predicted subsequent change in outcome (i.e., change in outcome from session
9 through 15).2 At level 1, I modeled within-patient change in outcome (i.e., worry or
distress) using a linear growth curve model, characterized by two parameters (intercept
and slope). Time was rescaled (from 0 to 1) so that the linear change coefficients would
reflect change in worry and general distress, respectively, across the second half of
treatment (Bolger & Laurenceau, 2013). I then centered the time variable at posttreatment
(session 15) so that the model intercepts would reflect posttreatment worry and distress.

2

Given the known influence of baseline medication status, motivation, and site in interaction with
medication status on the outcome variables of worry and global distress (see Westra et al., 2016), I
followed the same strategy as Westra et al. of residualizing out the effects of these three baseline variables
on each of the two outcomes. Thus, the outcome variables in the present study represent the variability in
worry and general distress not accounted for by these predictors.
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This model was estimated twice: once using the PSWQ scores, and once using the DASS
scores as the outcomes.
At level 2 in these models, the EB early alliance discrepancy slope estimates (i.e.,
convergence/divergence from sessions 2 through 8) generated from the previous analyses
were entered as predictors of subsequent change in outcome across treatment (outcome
slopes) and posttreatment outcome (outcome intercepts). (Additionally, I added initial
symptom severity, treatment condition, and patient and therapist session 1 alliance levels
as covariates given that bivariate correlations indicated that these variables might have a
bearing on outcome.) The general model equation was as follows:
Level-1 Model
Outcomeij = β0j + β1j*(TIMEij) + rij
Level-2 Model
β0j = γ00 + γ01*(treatment groupj) + γ02*(initial symptom severityj) + γ03*(patient WAIj) +
γ04*(therapist WAIj) + γ05*(early alliance convergencej) + u0j
β1j = γ10 + γ11*(treatment groupj j) + γ12*(initial symptom severityj) + γ13*(patient WAIj)
+
γ14*(therapist WAIj) + γ15*(early alliance convergencej j) + u1j
Finally, to examine the exploratory convergence by moderator questions, I first
created three interaction terms (i.e., the cross-products of session 1 patient-rated alliance,
session 1 therapist-rated alliance, and treatment condition with early alliance
convergence).3 Next, I fit three separate models that included all main effects and the
relevant convergence by moderator interaction term to test whether there was a
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As Aiken and West (1991) have recommended, the main effects for all interactions were mean-centered
prior to creating the respective interaction term.
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significant interactive effect on change in outcome over time or on posttreatment
outcome. Additionally, baseline symptom severity was included in these models as a
covariate. We fit these interaction models twice: once using the PSWQ scores, and once
using the DASS scores as the outcomes. The general alliance interaction model equation
was as follows:
Level-1 Model
Outcomeij = β0j + β1j*(TIMEij) + rij
Level-2 Model
β0j = γ00 + γ01*(initial symptom severityj) + γ02*(early alliance convergencej) +
γ03*(moderatorj)
+ γ04*(convergence by moderator interactionj) + u0j
β1j = γ10 + γ11*(initial symptom severityj) + γ12*(early alliance convergencej) +
γ13*(moderatorj) + γ14*(convergence by moderator interactionj) + u1j
3.3.1 Worry results. Results of the unconditional linear model of worry indicated
that the average worry level at session 15 was estimated to be -10.574 (p < .001), and the
average change in worry was negative and significant (γ10 = -10.87, p < .001).
Additionally, random effects indicated that there was significant variability in
posttreatment worry level and change in worry over the second half of treatment (ps <
.001).
Next, I fit an unconditional quadratic model to the data (see Table 5, column 1).
Results indicated that the average worry level at session 15 was -11.58 (p < .001), the
average change in worry was negative and significant (γ10 = -18.89, p < .001), and the
average rate of acceleration/deceleration in the rate of change in worry was negative and
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Recall that the outcome variables are residualized scores, allowing their coefficients to be negative.
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significant (γ20 = -8.18, p = .01). Additionally, random effects indicated that there was
significant variability in posttreatment worry level (p < .001) and change in worry (p =
.007), but not in the rate of acceleration/deceleration in the rate of change in worry (p =
.29). However, because the Wald statistic is a conservative test and can underestimate the
amount of variability in a parameter, I calculated a modified ICC, which revealed that
about 10% of the variability in worry was curvilinear. This suggested that patients might
vary significantly in their rates of acceleration/deceleration. Additionally, a model
comparison test revealed that the quadratic model fit the data significantly better than the
linear model, χ2(4) = 12.62, p = 0.01. Thus, I retained the quadratic model in all
subsequent analyses focused on predicting worry.
I next added early alliance convergence to the model as a predictor (see Table 5,
column 2). As expected, increased discrepancy (i.e., divergence) in early alliance ratings
was marginally significantly associated with greater posttreatment worry (γ01 = 74.61, p =
.08), significantly associated with a smaller reduction in worry across the second half of
treatment (γ11 = 168.40, p = .03), and associated with a positively accelerated worry
change trajectory (γ21 = 139.80, p = .03; see Figure 4). Put another way, decreases in
early alliance discrepancy (i.e., early alliance convergence) were associated with a greater
reduction in worry and a negatively accelerated change trajectory resulting in lower
posttreatment worry compared to patients with an increase in early alliance discrepancy
(i.e., early alliance divergence). The model with alliance convergence in it was a
marginally significantly better fit to the data than the unconditional quadratic model,
χ2(3) = 6.59, p = 0.09. Compared with the unconditional quadratic worry model, the
model with early alliance convergence resulted in a 3.99% reduction in unexplained
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variance in posttreatment worry, a 12.34% reduction in unexplained variance in
subsequent worry reduction, and a 23.63% reduction in the rate of variability in
acceleration/deceleration in the rate of worry change. Next, I added the covariates to the
model; the above associations held even when controlling for treatment condition, patient
and therapist ratings of session 1 alliance, and baseline worry (see Table 5, column 3).
3.3.2 Moderators.
3.3.2.1 Patient-rated session 1 alliance. Results indicated that patient-rated
session 1 alliance and early alliance convergence did not interact to predict posttreatment
worry (γ04 = -3.99, p = .37), subsequent change in worry (γ14 = 3.52, p = .67), or rate of
acceleration/deceleration in worry (γ24 = 7.68, p = .27), controlling for baseline worry
(see Table 6). Also, the model with the patient session 1 alliance by convergence
interaction term was not a significantly better fit to the data than the model with only the
main effects and covariate, χ2(3) = 3.68, p = .30.
3.3.2.2 Therapist-rated session 1 alliance. Similarly, therapist-rated session 1
alliance and early alliance convergence did not interact to predict posttreatment worry
(γ04 = -2.11, p =.65), subsequent change in worry (γ14 = -11.02, p =.20), or rate of
acceleration/deceleration in worry (γ24 = -6.77, p = .35), controlling for baseline worry
(see Table 7). Also, the model with the therapist session 1 alliance by convergence
interaction term was not a significantly better fit to the data than the model with only the
main effects and covariate, χ2(3) = 2.18, p > .50.
3.3.2.3 Treatment condition. Finally, treatment group and early alliance
convergence did not interact to predict posttreatment worry (γ04 = -50.46, p =.56),
subsequent change in worry (γ14 = -236.81, p =.16), or rate of acceleration/deceleration in
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worry (γ24 = -123.83, p = .39), controlling for baseline worry (see Table 8). Also, the
model with the treatment by convergence interaction term was not a significantly better
fit to the data than the model with only the main effects and covariate, χ2(3) = 3.39, p =
.34.
3.3.3 General distress results. Results of the unconditional linear model of
general distress indicated that the average distress level at session 15 was estimated to be
-3.79 (p = .002), and the average change in distress from session 10 to 15 was negative
and significant (γ10 = -5.33, p < .001; see Table 9, column 1). Additionally, random
effects indicated that there was significant variability in posttreatment distress level and
change in distress (ps < .001). (Unlike with worry, I did not fit a quadratic model to the
distress variable, as there were only three measurements occasions available after session
8.)
I next added early alliance convergence to the model as a predictor (see Table 9,
column 2). As expected, increased discrepancy (i.e., divergence) in early alliance ratings
was significantly associated with greater posttreatment distress (γ02 = 60.96, p = .015)
and with a smaller decrease in distress from session 10 to 15 (γ11 = 69.83, p = .01). Put
another way, early decreases in alliance discrepancy (i.e., convergence) were associated
with lower posttreatment distress and steeper reductions in distress (see Figure 5). The
model with early alliance convergence was a significantly better fit to the data than the
unconditional model, χ2(2) = 9.38, p = .009. Compared with the unconditional distress
model, the model with early alliance convergence resulted in an 8.79% reduction in
unexplained variance in posttreatment distress level, and a 17.88% reduction in
unexplained variance in subsequent distress reduction. The above associations held even
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when controlling for treatment condition, patient and therapist ratings of session 1
alliance, and baseline distress (see Table 9, column 3).
3.3.4 Moderators.
3.3.4.1 Patient-rated session 1 alliance. Results indicated that patient-rated
session 1 alliance and early alliance convergence interacted to marginally significantly
predict posttreatment distress (γ04 = -4.15, p =.09) and to significantly predict subsequent
distress change (γ14 = -5.43, p =.04), controlling for baseline distress (see Table 10). This
interactive effect appeared to be primarily driven by differences between patient-therapist
dyads who were characterized by both low patient-rated session 1 alliance levels and low
alliance convergence; patients in these dyads, actually showed a slight increase in
distress across the second half of treatment (see Figure 6). In contrast, dyads that were
characterized by any other combination of these variables (i.e., low alliance
convergence/high patient-rated alliance, high alliance convergence/low patient-rated
alliance, and high alliance convergence/high patient-rated alliance) all showed relatively
equal rates of distress reduction across the second half of treatment. The model with the
patient-rated session 1 alliance by early alliance convergence interaction was a
marginally significantly better fit to the data than the model with only the two main
effects and covariate, χ2(2) = 4.96, p = .08. Compared to the model with the main effects
and covariate (i.e., early convergence/divergence, patient session 1 alliance, and baseline
distress), the model with the interaction term resulted in a 4.87% reduction in
unexplained variance in posttreatment distress level, and a 14.78% reduction in
unexplained variance in subsequent distress reduction.
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3.3.4.2 Therapist-rated session 1 alliance. In contrast, therapist session 1
alliance and early alliance convergence did not interact to predict posttreatment distress
(γ04 = -3.13, p = .22) or subsequent change in distress (γ14 = -2.84, p = .31), controlling for
baseline distress (see Table 11). The model with the therapist session 1 alliance by early
alliance convergence interaction term was not a significantly better fit to the data than the
model with only the main effects and covariate, χ2(2) = 0.14, p > .5.
3.3.4.3 Treatment condition. Finally, treatment group and early alliance
convergence did not interact to predict posttreatment distress (γ04 = -27.73, p = .57) or
subsequent change in distress (γ14 = -63.28, p = .26), controlling for baseline distress (see
Table 12). The model with the treatment group by early alliance convergence interaction
term was not a significantly better fit to the data than the model with only the main
effects and covariate, χ2(2) = 1.31, p > .5.
3.4 Evidence of Patient-Therapist Session Progress Convergence
3.4.1 Descriptive evidence of session progress convergence. The mean session
progress discrepancy scores (absolute value) for patients and therapists at each session
are presented in Figure 7. The mean discrepancies between patient and therapist ratings
of session progress were smallest early in treatment (M discrepancy for session 1 = 3.87,
SD = 2.84) and larger later in treatment (M for session 14 = 4.99, SD = 3.20), suggesting
that, on average, patients’ and therapists’ progress ratings became more discrepant over
time, reflecting a pattern of divergence. Moreover, patient-therapist divergence (i.e.,
increase in discrepancy) appeared steepest during the first half of treatment and seemed
to level off during the second half of treatment.
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3.4.2 Estimating session progress discrepancies at each session. The series of
2-level difference score models (completed above for the alliance variable and replicated
here for session progress) indicated significant discrepancy, on average, and significant
variability around the average discrepancy in patient-therapist session progress ratings at
each session. EB discrepancy estimates for each patient-therapist dyad at each session
were output from each model’s HLM level-2 residual file to be used as the outcome
variable in the models testing change in session progress similarity/discrepancy over
time.
3.4.3 Modeling session progress discrepancy change over time (i.e.,
convergence/divergence). Prior to fitting our convergence models, the EB discrepancy
scores required transformation. Given the coding of the discrepancy indicator, dyads in
which patients rated session progress higher than their therapist received a negative
discrepancy score, while dyads in which the therapist had a higher session progress rating
received a positive discrepancy score. Although on average patients’ session progress
ratings were lower than therapists’ ratings at each session (recall that on the SPS, lower
scores reflect greater progress), there were 21 dyads with negative discrepancies (i.e., the
patient rated the session as less helpful compared to his or her therapist, at one or more
sessions). Additionally, there were 20 dyads whose discrepancy scores changed from
positive to negative across time, rendering it impossible to meaningfully model the rate of
change in discrepancy for these dyads. Thus, as with the alliance, I used the absolute
value of the HLM-derived EB discrepancies obtained for each measurement occasion to
address the problem of changing signs (Laws et al., 2016). Unlike the transformation of
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the alliance discrepancies, this transformation did not result in substantially skewed
distributions (skewnesses all < .6), so no further transformation was required.
These absolute value EB discrepancy scores for sessions 2, 4, 6, 8, 10, 12, and 14
were used as the outcome in a model that tested session progress similarity change across
treatment. In this model, time was rescaled to capture the total change over the entire
therapeutic period (Bolger & Laurenceau, 2013). Thus, the linear slope parameter
represented change in discrepancy across the entire psychotherapy period for the average
dyad.
Results indicated that session progress discrepancy significantly increased over
the course of psychotherapy (see Table 13, column 1). Specifically, the average session
progress discrepancy at session 2 was estimated as 1.22 (p < .001), which increased
significantly by the end of psychotherapy (γ10 = .14, p = .03). Although most dyads
showed a pattern of increasing discrepancy in session progress ratings (i.e., divergence),
there was marginally significant variability in discrepancy change (p = .05); in fact, some
dyads (n = 16) became more similar (i.e., a pattern of convergence) in their session
progress ratings across therapy. Figure 8 displays the rate of change in session progress
discrepancy across treatment on average (Panel A) and the variability around the average
(Panel B). Next, similar to the alliance data, I tested a quadratic model of session progress
convergence/divergence across treatment (see Table 13, column 2); results indicated that
there was no significant curvilinear pattern to session progress discrepancy change, on
average (γ20 = -0.22, p = .28), no significant between-dyad variability in the rate of
acceleration in session progress discrepancy change across treatment (τ22 = 0.19, p > .50),
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and the quadratic model was not a better fit to the data than the linear model, χ2(4) = 3.34,
p > .5.
To test for session progress similarity change across the first half of treatment, the
aforementioned model was repeated using the absolute value EB discrepancy scores for
sessions 2 through 8 as the outcome, with time rescaled to represent change across the
first half of psychotherapy. Results indicated that session progress discrepancy increased
significantly across the first half of psychotherapy. Session progress discrepancy at
session 2 was estimated as γ00 = 1.24 (p < .001), which increased significantly by session
8 (γ10 = .12, p = .04). However, although there was significant variability in discrepancy
at session 2 (p < .001), there was no significant variability around the rate of change in
discrepancy across the first half of treatment (p > .5). Because of this, based on a visual
inspection of the data, I examined change in session progress discrepancy from sessions 2
through 5, as this period appeared to capture the greatest amount of change in patienttherapist session progress discrepancy (see Table 13, column 3). Results indicated that
session progress discrepancy at session 2 was estimated as γ00 = 1.20 (p < .001), which
increased significantly by session 5 (γ10 = .20, p = .008). Additionally, there was
significant variability in discrepancy at session 2 (p < .001) and in the rate of change in
discrepancy from sessions 2 through 5 (p = .008). Figure 9 displays the rate of change in
session progress discrepancy from session 2 through 5 on average (Panel A) and the
variability around the average (Panel B). From the aforementioned linear model (i.e.,
linear change in session progress discrepancy from session 2 through 5), EB coefficients
of each dyad’s estimated change in discrepancy were output for use as predictors in the
primary analyses.
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Additionally, due to the additional inherent nesting in the data, I ran an
unconditional 3-level model to examine the amount of variability in early session
progress convergence/divergence (again, sessions 2 through 5 for this variable) that was
accounted for by the therapist. (Other than the time period used, the structure of this
model was identical to the 3-level alliance discrepancy model described above.)
Level-1 Model
SPSijk = π0jk + π1jk*(TIMEijk) + eijk
Level-2 Model
π0jk = β00k + r0jk
π1jk = β10k + r1jk
Level-3 Model
β00k = γ000 + u00k
β10k = γ100 + u10k
Results of this model (see Table 14) indicated that the average therapist session
progress discrepancy at session 2 was estimated as γ000 = 1.16 (p < .001), which increased
non-significantly by session 5 (γ100 = 0.07, p = .42). Additionally, level-2 random effects
indicated that there was significant within-therapist variability (i.e., between-patients in a
given therapist’s caseload) from their own average rate of change in session progress
discrepancy (p < .001), but an examination of the level-3 random effects indicated that
there was no significant between-therapist variability in the rate change in discrepancy (p
> .5). An ICC revealed that aproximately 11.61% of the variability in the dyad-level
discrepancy scores was due to the therapist (intercept), and only 3.19% of the variability
in the rate of change in session progress discrepancy over time was due to therapists
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(slopes), suggesting that about 97% of the variability in these discrepancy slopes was
unique to each dyad. In other words, even though each therapist saw multiple patients,
the correlation between two patients’ rates of change in discrepancy who were seen by
the same therapist was only about .03. Thus, I retained the EB coefficients of each dyad’s
estimated change in discrepancy from the 2-level model for their use as predictors in our
subsequent analyses. (As with the alliance discrepancy models, the 2-level model of
session progress discrepancy change was also a more reliable model than the 3-level
model, suggesting that the 2-level model might produce more reliable EB discrepancy
change estimates.)
3.5 Testing Early Session Progress Convergence as a Predictor of Worry and
General Distress
Prior to testing the primary session progress research questions, I examined
descriptive statistics and intercorrelations between all relevant predictors/moderators (i.e.,
early progress convergence/divergence, patient- and therapist-rated session 1 progress,
and treatment condition) and the baseline covariates of worry and distress (see Table 15).
All of the variables appeared relatively normally distributed (skewness values ranged
from -0.21 to .12). Intercorrelations between predictors were low to moderate (rs range
from -.43 to .36), suggesting no problematic collinearity.
I next tested whether rate of change in session progress discrepancy from session
2 through 5 predicted subsequent change in outcome (i.e., change in outcome from
session 6 to session 15). At level 1, I modeled within-patient change in outcome (i.e.,
worry or distress) using a linear growth curve model, characterized by two parameters
(intercept and slope). Time was again rescaled (from 0 to 1) so that the linear change
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coefficients would reflect change in worry and general distress, respectively, from
session 6 through 15. I then centered the time variable at posttreatment (session 15) so
that the model intercepts would reflect posttreatment worry and distress. This model was
estimated twice: once using the PSWQ scores, and once using the DASS scores as the
outcomes.
At level 2 in these models, the EB early session progress discrepancy slope
estimates (i.e., convergence/divergence from sessions 2 through 5) generated from the
previous analyses were entered as predictors of subsequent change in outcome across
treatment (outcome slopes) and posttreatment outcome (outcome intercepts).
(Additionally, I added initial symptom severity, treatment condition, and patient and
therapist session 1 progress levels, and therapist-rated as covariates given that bivariate
correlations indicated that these variables might have a bearing on outcome.) The general
model equation was as follows:
Level-1 Model
Outcomeij = β0j + β1j*(TIMEij) + rij
Level-2 Model
β0j = γ00 + γ01*(treatment groupj) + γ02*(initial symptom severityj) + γ03*(patient SPSj) +
γ04*(therapist WAIj) + γ05*(early SPS convergencej) + u0j
β1j = γ10 + γ11*(treatment groupj j) + γ12*(initial symptom severityj) + γ13*(patient SPSj) +
γ14*(therapist SPSj) + γ15*(early SPS convergencej j) + u1j
Finally, to examine the exploratory convergence/divergence by moderator
questions, I first created three interaction terms (i.e., the cross-products of session 1
patient-rated progress, session 1 therapist-rated progress, and treatment condition with
early session progress convergence). Again, the main effects for all interactions were
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mean-centered prior to creating the interaction terms. Next, I fit three separate models
that included all main effects and the relevant convergence by moderator interaction term
to test whether there was a significant interactive effect on change in outcome over time
or on posttreatment outcome. Additionally, baseline symptom severity was included in
these models as a covariate. I fit these interaction models twice: once with the PSWQ as
the outcome measure, and once with the DASS as the outcome measure. The general
session progress interaction model equation was as follows:
Level-1 Model
Outcomeij = β0j + β1j*(TIMEij) + rij
Level-2 Model
β0j = γ00 + γ01*(initial symptom severityj) + γ02*(early session progress convergencej) +
γ03*(moderatorj) + γ04*(convergence by moderator interactionj) + u0j
β1j = γ10 + γ11*(initial symptom severityj) + γ12*(early session progress convergencej) +
γ13*(moderatorj) + γ14*(convergence by moderator interactionj) + u1j

3.5.1 Worry results. As the previous worry models suggested that a quadratic
model best captured the shape of patients’ worry change, I first fit an unconditional
quadratic model to the data (see Table 16, column 1). Results indicated that the average
worry level at session 15 was -11.02 (p < .001), the average change in worry from session
6 to 15 was negative and significant (γ10 = -20.71, p < .001), and the average rate of
acceleration/deceleration in the rate of change in worry was nonsignificant and negative
(γ20 = -5.44, p = .15). Additionally, random effects indicated that there was significant
variability in posttreatment worry level (p < .001), change in worry (p = .007), and in the
rate of acceleration/deceleration in rate of change in worry (p < .001). Thus, I retained the
quadratic model in all subsequent analyses predicting worry.
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I next added early session progress convergence/divergence to the model as a
predictor (see Table 16, column 2). Unexpectedly, increased discrepancy (i.e.,
divergence) in early session progress ratings was marginally significantly associated with
lower posttreatment worry (γ01 = -16.11, p = .05), non-significantly associated with a
smaller subsequent reduction in worry across sessions 5 through 15 (γ11 = 2.01, p = .91),
and non-significantly associated with a positively accelerated change trajectory (γ21 =
14.05, p = .38; see Figure 10). The model with session progress convergence/divergence
in it was not a better fit to the data than the unconditional quadratic model, χ2(3) = 4.91, p
= 0.18. Compared with the unconditional worry model, the model with early session
progress convergence resulted in a 4.91% reduction in the unexplained variance in
posttreatment worry. Next, I added our covariates to the model; session progress
convergence/divergence was no longer significantly associated with posttreatment worry
when controlling for treatment condition, patient and therapist ratings of session 1
progress, and baseline worry (see Table 16, column 3).
3.5.2 Moderators.
3.5.2.1 Patient-rated session 1 session progress. Results indicated that patientrated session 1 progress and early convergence did not interact to predict posttreatment
worry (γ04 = 0.03, p = .99), subsequent worry change (γ14 = -5.69, p = .38), or rate of
acceleration/deceleration in worry (γ24 = -6.17, p = .28), controlling for baseline worry
(see Table 17). The model with the patient session 1 progress by convergence interaction
term was not a significantly better fit to the data than the model with only the main
effects and covariate, χ2(3) = 1.36, p > .50.
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3.5.2.2 Therapist-rated session 1 session progress. Similarly, therapist-rated
session 1 progress and early convergence did not interact to predict posttreatment worry
(γ04 = 0.43, p = .91), subsequent worry change (γ14 = -1.54, p = .85), or rate of
acceleration/deceleration in worry (γ24 = -2.72, p = .71), controlling for baseline worry
(see Table 18). The model with the treatment by convergence interaction term was not a
significantly better fit to the data than the model with only the main effects and covariate,
χ2(3) = 0.40, p > .50.
3.5.2.3 Treatment condition. Finally, treatment group and early session progress
convergence did not interact to predict posttreatment worry (γ04 = -15.19, p = .32),
subsequent change in worry (γ14 = -6.05, p = .83), or rate of acceleration/deceleration in
worry (γ24 = 11.70, p = .73), controlling for baseline worry (see Table 19). The model
with the treatment by convergence interaction term was not a significantly better fit to the
data than the model with only the main effects and covariate, χ2(3) = 1.10, p > .50.
3.5.3 General distress results. Results of the unconditional linear model of
distress indicated that the average distress level at session 15 was estimated to be -3.86 (p
= .002), and the average change in distress from session 6 to 15 was negative and
significant (γ10 = -9.18, p < .001). Additionally, random effects indicated that there was
significant variability in posttreatment distress level and change in distress (ps < .001).
Next, I fit an unconditional quadratic model to the data (see Table 20, column 1). Results
indicated that the average posttreatment distress level was estimated to be -3.79 (p =
.002), the average change in distress was negative and significant (γ10 = -9.51, p = .04),
and the average rate of acceleration/deceleration in the rate of change in distress was
negative and nonsignificant (γ20 = -0.40, p = .93). Additionally, random effects indicated
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that there was significant variability in posttreatment distress, rate of change in distress at
posttreatment, and rate of acceleration/deceleration in rate of change in distress (ps <
.001); see Table 20, column 1). A model comparison test revealed that the quadratic
model was a marginally significantly better fit to the data than the linear model, χ2(4) =
7.33, p = .12. Thus, I retained the quadratic model in all subsequent analyses focused on
predicting of distress.
I next added early session progress convergence to the model as a predictor (see
Table 20, column 2). Counter to our hypotheses, increased discrepancy (i.e., divergence)
in early session progress ratings was not associated with posttreatment distress (γ01 = 1.04, p = .84) or with distress reduction from session 6 through posttreatment (γ11 =
24.72, p = .20). However, also counter to our hypotheses, increased discrepancy was
associated with a positively accelerated change trajectory (γ21 = 40.09, p = .03; see Figure
11), suggesting that, on average, patient-therapist dyads who became less similar (more
discrepant) in their session progress ratings had a faster subsequent reduction in distress.
The model with early session progress convergence in it was a significantly better fit to
the data than the unconditional quadratic model, χ2(3) = 9.89, p = 0.02. Compared with
the unconditional quadratic distress model, the model with early session progress
convergence resulted in a 16.29% reduction in the rate of variability in
acceleration/deceleration in the rate of distress change. Next, I added our covariates to the
model; early session progress convergence remained a significant predictor of the rate of
acceleration/deceleration in distress change even when controlling for treatment
condition, patient and therapist ratings of session 1 progress, and baseline distress (see
Table 20, column 3).

45

3.5.4 Moderators.
3.5.4.1 Patient-rated session 1 session progress. Results indicated that patientrated session 1 progress and early convergence interacted to marginally significantly
predict subsequent change in distress (γ14 = -13.02, p =.06) and to significantly predict the
rate of acceleration/deceleration in distress change (γ24 = -15.28, p =.02), controlling for
baseline distress (see Table 21). However, the interaction term did not predict
posttreatment distress (γ04 = 0.36, p = .84). In other words, the interaction of patient-rated
session 1 progress was not associated with different overall levels of distress at
posttreatment, rather it was associated with different during-treatment change trajectories
(i.e., the interaction impacted the pattern of patients’ distress change). Higher patientrated session progress (indicating that the session was less helpful) combined with either
convergence or divergence resulted in distress change trajectories that appeared roughly
linear and resulted in the least overall distress change by posttreatment (see Figure 12).
For patients with low session progress (indicating that the session was more helpful),
those with lower levels of session progress divergence had a positively accelerated
change trajectory, whereas patients with higher levels of divergence had a negatively
accelerated change trajectory. However, as depicted in Figure 12, both of these change
trajectories resulted in approximately equal distress change by posttreatment. The model
with the patient-rated session 1 progress by early convergence interaction was a
marginally significantly better fit to the data than the model with only the two main
effects and covariate, χ2(3) = 5.79, p = .12. Compared to the model with the main effects
and covariate (i.e., early convergence, patient session 1 progress, and baseline distress),
the model with the interaction term resulted in an 14.36% reduction in the unexplained
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variance in subsequent distress reduction, and a 20.68% reduction in the unexplained
variance in the rate of acceleration/deceleration in distress change.
3.5.4.2 Therapist-rated session 1 session progress. In contrast, therapist-rated
session 1 progress and early convergence did not interact to predict posttreatment distress
(γ04 = -1.18, p = .61), subsequent change in distress (γ14 = -1.80, p = .80), or rate of
acceleration/deceleration in distress change (γ24 = 0.30, p = .97), controlling for baseline
distress (see Table 22). The model with the therapist-rated session 1 progress by
convergence interaction term was not a significantly better fit to the data than the model
with only the main effects and covariate, χ2(3) = 0.51, p > .50.
3.5.4.3 Treatment condition. Finally, treatment group and early session progress
convergence did not interact to predict posttreatment distress (γ04 = -2.08, p = .84),
subsequent distress change (γ14 = 50.83, p = .20), or rate of acceleration/deceleration in
distress (γ24 = 34.36, p = .37), controlling for baseline distress (see Table 23). The model
with the treatment by convergence interaction term was not a significantly better fit to the
data than the model with only the main effects and covariate, χ2(3) = 5.40, p = .14.
3.6 Therapist Effects on Worry and General Distress
I did not examine therapist effects on worry or general distress outcomes as
Westra et al. (2016) reported that less than 1% of the variability in patients’ posttreatment
worry/distress and during-treatment rates of change in worry/distress were accounted for
by the therapist.
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CHAPTER 4
DISCUSSION
The goals of this study were to examine patterns of patient-therapist convergence
in their ratings of alliance and session progress throughout treatment, and to test whether
greater convergence on these variables was associated with treatment outcome across two
psychotherapies (MI-CBT and CBT) for GAD. The results for the alliance convergence
models and the session progress models are summarized and discussed in turn.
4.1 Alliance Convergence
As predicted, patients and their therapists became, on average, more similar in
their ratings of their alliance quality, both over the early part of treatment (early alliance
convergence) and the entirety of treatment. Moreover, greater early alliance convergence
(sessions 2-8) was associated with greater subsequent reductions in worry (sessions 9-15)
and general distress (sessions 10-15), as compared to dyads that evidenced less early
alliance convergence (or who experienced early alliance divergence). Although these
associations did not differ based on the therapists’ initial alliance perception or the
treatment condition, the association between alliance convergence and subsequent
distress (but not worry) reduction differed depending on patients’ initial alliance
perception; the combination of a low initial patient-perceived alliance and the subsequent
experience of low alliance convergence (or even divergence) may particularly hinder
distress reduction.
That patients and their therapists converged over time in their alliance perceptions
replicated the findings of two previous studies (Hersoug et al., 2001; Laws et al., 2016).
Together, these results support Bordin’s (1979) notion that an adaptive patient-therapist
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alliance is characterized by increasing patient-therapist instrumental attunement
(goal/task agreement) and emotional attunement (shared bond). Moreover, the present
results extend prior work by examining more extensively the timeframe and shape of
patient-therapist alliance convergence; that is, I examined session-by-session alliance
convergence both in an early phase and across the full treatment, whereas Hersoug et al.
and Laws et al. examined the alliance more sporadically. With these more frequent
alliance measurements, I found that the greatest amount of patient-therapist convergence
occurred early in treatment; in fact, the average change in alliance discrepancy across the
first half of treatment was approximately equivalent to the average change in alliance
discrepancy across all of therapy (i.e., γ10 = -.14 in both models). Perhaps this is not
surprising; when two people enter into a novel relationship, it may take time to start
perceiving their dyadic field in an attuned manner. However, it appears that patients and
therapists, at least on average, can come to see their relationship more similarly rather
efficiently. Such attunement, then, may be a malleable dyadic process early, whereas later
such attunement appears more stable (perhaps because of there being less room to
converge after the early formative stage).
Notably, there was little evidence that the degree of patient-therapist early alliance
convergence differed depending on the person of the therapist; that is, the vast majority
of convergence variability (i.e., about 95%) was accounted for by the unique therapy
dyad. Thus, achieving alliance convergence may depend more on the specific dyad and
their interactions than on the general attunement-fostering skill of the therapist.
Interestingly, this finding is consistent with previous research that examined the alliance
separately from both patient and therapist perspectives (but not their convergence), and
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found that variability in these ratings was more attributable to the unique patient-therapist
dyad than to the contributions of particular therapists (Marcus et al., 2009).
Moreover, the dyadic process of early alliance convergence predicted subsequent
during-treatment reductions in worry and distress. This relation between convergence and
positive outcome replicates the one previous study that examined this association (but in
a sample of patients receiving treatment for chronic depression; Laws et al., 2016). The
present findings also extend Laws et al.’s findings, not only to the treatment of GAD, but
also by adding temporal precedence between the predictor (early alliance convergence
from session 2-8) and subsequent worry and distress reduction (from session 9-15 and
10-15, respectively) during the acute treatment period. (As previously noted, this
temporal precedence affords greater confidence that convergence precedes subsequent
improvement rather than the reverse.) Additionally, these associations held even when
controlling for initial patient- and therapist-rated alliance quality, suggesting that they
were not merely capturing a main effect of early alliance. Although the precise
mechanisms through which patient-therapist alliance convergence affects improvement
remain unknown, there are several possible explanations.
First, it could simply be that the process of becoming more aligned with one’s
therapist on emotions, perceptions, and attitudes represents a novel, corrective experience
for the patient who has not historically experienced such convergences in other important
relationships (Castonguay & Hill, 2012). As Anderson and Keltner (2004) have argued,
such convergence is one marker of healthy close relationships. Thus, such a healthy
relational experience with one’s therapist, perhaps irrespective of the goals, tasks, and
strategies of the treatment (or at least as a complement to them), may help to directly
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alleviate suffering. This may be particularly true when the lack of such convergences
contributes to the etiology of one’s presenting concerns. Although speculative, one could
consider this to be the case for patients with GAD given that this condition has been
associated with interpersonal dysfunction in general (Newman, Crits-Christoph, &
Szkodny, 2013), a bevy of interpersonal themes in worry content (Roemer, Molina, &
Borkovec, 1997), and less secure attachment (Newman, Llera, Erickson, Przeworski, &
Castonguay, 2012)—all of which could be related to a lack of experienced convergence,
or healthy attunement, in important relationships. When experiencing convergence with a
therapist, a person with GAD might, at least in part, be experiencing attachment that is
more synchronous. And, again, this could help alleviate suffering in itself. Thus, a
clinical implication would be for therapists to assess dyadic alliance convergence via
routine alliance monitoring on parallel alliance instrumentation. With the knowledge
gained from such ongoing assessment, therapists and their patients can strive to increase,
achieve, and maintain convergence over time (perhaps through direct
metacommunication about elements of their relationship on which they diverge; for a
review of strategies that might explicitly foster agreement on different alliance facets see
Constantino, Castonguay, Zack, & DeGeorge, 2010).
Second, social psychological research points to several positive general relational
experiences that result from greater dyadic convergence, including more perceived
closeness/trust/relationship satisfaction, greater intention to stay in the relationship, and
longer actual relationship tenures (e.g., Anderson & Keltner, 2004). It is plausible that
these positive relational experiences in general could also translate directly to therapyspecific experiences in the form of secure attachment to the therapist, motivation for
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treatment, and treatment engagement, respectively, all of which have been associated
with positive treatment outcomes (e.g., Levy, Ellison, Scott, & Bernecker, 2011;
Lombardi, Button, & Westra, 2014; Kazantzis, Whittington, Dattilio, 2010, respectively).
The notion here is that greater dyadic convergence might give rise to adaptive
intermediate outcomes in the psychotherapy process, and in this vein, future research
should examine possible mediational pathways from early alliance convergence to, for
example, higher treatment engagement, which may in turn predict adaptive treatment
outcome.
Third, alliance convergence might just very specifically be about the patienttherapist alliance construct. The process of becoming more aligned could be capturing
healthy therapeutic alliance development; that is, as a patient and therapist start
perceiving their relational field in a more attuned manner, they may have achieved a
favorable condition (of well-aligned trust, security, and direction) that supports the
challenging “work” of therapy. In this sense, early alliance convergence might be a
precondition for the more technical elements of psychotherapy to take hold. This would
again reflect a mediational pathway to be tested: from early alliance convergence to, for
example, more frequent worry exposure, which may in turn predict adaptive treatment
outcome.
Finally, as Laws et al. (2016) suggested, increases in patient-therapist alliance
discrepancies over time (i.e., divergence) could be negatively associated with treatment
outcomes because they are capturing alliance ruptures, or breakdowns/tensions in the
collaborative patient-therapist relationship (Safran & Muran, 2006). However, dyadic
divergence might be capturing a special type of rupture that is different from the more
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typically observed confrontation and withdrawal ruptures when measured from one
person’s perspective (i.e., patient, therapist, or observer). Specifically, a pattern of
increasing alliance discrepancy (measured dyadically) could reflect an unnoticed rupture
that is continuing to worsen over time (i.e., an alliance pattern characterized by increasing
misattunement, even if there is not overt confrontation or withdrawal). If indeed such
divergence were a form of alliance rupture, it would make sense that it would relate to
poorer treatment outcome just like other forms of tension/rupture (Eubanks-Carter,
Muran, & Safran, 2010). As a concrete example, both patient and therapist will possess
their own perceptions of their alliance; the patient could believe that they have a very
trusting relationship and high agreement on the tasks and goals of treatment, whereas the
therapist might also believe they have a high level of task/goal agreement, but perceive
relational trust as low. Both partners, of course, likely believe that they perceive the
relationship accurately and could be unaware that they differ on the trust element. Over
time, if the patient continues to believe the relationship is becoming more and more
trusting and emotionally close, whereas the therapist sees it as stagnant (a pattern of
divergence), this would represent a subtle and likely unnoticed relational misattunement
that could, like any alliance rupture or misalignment, be toxic. This type of rupture,
though, would likely go unnoticed without dyadic measurement of said attunement. An
implication of this for both clinical work and future research is that routine dyadic
alliance monitoring is key for heightening awareness to this potentially nuanced rupture
manifestation. With such awareness, the dyad can work toward greater convergence over
time, which in this frame might represent a specific form of rupture repair (and rupture
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repair in general has been associated with better treatment outcomes; Safran, Muran, &
Eubanks-Carter, 2011).
The present study’s exploratory moderator analyses provide additional
information on the circumstances under which alliance convergence/divergence is
associated with treatment outcomes. First, the alliance convergence by treatment group
moderator analyses suggested that the convergence-outcome association did not differ
depending on treatment type (MI-CBT vs. CBT alone). This finding suggests that alliance
convergence might represent an adaptive relational process that occurs across different
types of therapies (i.e., a common factor), including those that are more directive (i.e.,
CBT) and those that incorporate more client-centered or non-directive strategies in the
face of patient resistance (i.e., MI-CBT). This common factor notion was also supported
in the previous study that examined alliance convergence in relation to outcome across
two treatments for chronic depression (Laws et al., 2016).
Second, the convergence/divergence-treatment outcome association also did not
differ depending on the therapists’ initial perceptions of alliance quality. Perhaps for
therapists, it matters more for outcome that they become increasingly attuned to their
patient’s perceptions of the alliance over time and it matters less how positively they
initially view the level of their alliance quality. In contrast, I found some evidence (albeit
preliminary) that the association between dyadic alliance convergence and subsequent
distress reduction differed depending on the patient’s initial perception of the alliance; for
dyads in which patients perceived the initial alliance (session 1) as being low quality, the
degree to which these dyads converged or diverged mattered a great deal for patient
outcomes. Specifically, if these dyads subsequently converged, then patients tended to
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achieve roughly comparable outcomes to dyads with higher quality initial patientperceived alliances. However, if these dyads subsequently diverged, patients actually got
more distressed, on average. Thus, a combination of low initial patient-perceived alliance
quality and high patient-therapist alliance divergence could be an important prognostic
marker for poor patient distress outcomes.
Recall that Marmarosh and Kivlighan (2012) also found an interactive effect of
early alliance quality and similarity/attunement in patient-therapist alliance ratings (at one
point in time) on patient outcomes. Specifically, they found that alliance similarity was
more strongly associated with outcome for high versus low patient-perceived alliance
dyads. In the present study, I found that the experience of alliance convergence or
divergence mattered most for dyads with low versus high patient-perceived alliance.
Although these findings differ somewhat, they both provide preliminary support for the
notion that the associations between both patient-therapist alliance discrepancy and
outcome and alliance discrepancy change (convergence/divergence) and outcome may
depend on the patient’s initial perceptions of alliance quality. Thus, although we have
called for the importance of dyadic level alliance measurement, the fact that such
measurement continues to capture the patient’s individual alliance perspective remains
valuable clinical information. For example, it may be that the use of alliance rupturerepair strategies could be especially indicated for dyads that also feature low early
patient-perceived alliance quality in addition to a pattern of alliance divergence.
Alternatively, a pattern of alliance convergence, as noted above, could be a signal for
therapists to capitalize on their highly attuned collaborative bond with their patients (no
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matter the patient’s early perception of alliance quality) by engaging in specific change
interventions.
However, this interactive effect must be interpreted with some caution, as it was
only found to influence distress reduction, but not worry reduction. Although it remains
unknown why this interactive association was not found for both outcomes in this study,
there could be statistical reason; that is, there may have been power constraints for the
worry outcome given the inclusion of a quadratic parameter (which was not included in
the distress models). Or, the effect for worry could be smaller, thus requiring more power
to detect it. Alternatively, it could indeed be that the interactive effect differs depending
on the type of outcome (e.g., general, inclusive distress versus the specific symptom of
worry), which requires further investigation.
4.2 Session Progress Convergence
Counter to my prediction, patients and their therapists became, on average, more
dissimilar in their ratings of session progress, both over the early part of treatment (early
session progress divergence) and the entirety of treatment. Moreover, and also
unexpectedly, greater early session progress divergence (sessions 2-5) was associated
with lower posttreatment (session 15) worry and a faster subsequent reduction in distress
(sessions 6-15), as compared to dyads that evidenced less early session progress
divergence (or who experienced early session progress convergence). None of the
associations between session progress divergence and the various patient outcomes
differed based on the therapists’ initial session progress perception or the treatment
condition. However, initial patient-rated session progress and early session progress
convergence/divergence interacted to marginally predict subsequent change in distress

56

and to significantly predict the rate of acceleration/deceleration in distress change. For
dyads in which patients perceived more progress in the initial session, subsequent session
progress convergence related to a positively accelerated distress change trajectory (i.e.,
they showed more distress over part of therapy before evidencing a reduction later); for
the same dyads in which patients perceived more progress in the initial session,
subsequent session progress divergence related to a negatively accelerated distress
change trajectory (i.e., they showed a faster decrease in distress before leveling off). In
brief, for those dyads with patients reporting high initial session progress and either
subsequent progress convergence or divergence, distress scores ended up in comparable
place by the end of treatment; however, the trajectories to get there were notably
different. There was no interactive effect of initial session progress and subsequent
session progress convergence/divergence on the worry outcomes.
Although the finding that most patient-therapist dyads diverged over time in their
ratings of session progress was unpredicted (in light of general attunement/convergence
theories and prior research on alliance convergence), there are several plausible (though
certainly tentative) explanations. First, perhaps patients generally tend to see their
progress as increasing over time, whether or not their therapist also sees this pattern. This
pattern might accurately reflect progress, or it could be a mechanism to reduce cognitive
dissonance (Festinger, 1957). If the latter, it might understandably reflect a general
pattern of therapists tending to be more cautious than their patients when evaluating
progress—what Atzil-Slonim et al. (2015) termed a “better safe than sorry” pattern. If the
former, a second explanation for the divergence pattern might simply reflect that
therapists are not very accurate in perceiving actual progress in their patients (though
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there remains the question of what is the “truth” when it comes to progress). Finally,
another reason the present session progress findings do not square with general
attunement/convergence theories is that session progress is not a true relational variable
(whereas the alliance is). Of course, all of these speculations are tentative at best and
require replication and further clarification.
Consistent with the alliance models in this study, there was little evidence that the
degree of patient-therapist early session progress divergence differed depending on the
person of the therapist. Session progress divergence may depend more on the specific
dyad than on the therapist’s specific contribution to misattunement.
With regard to predicting outcome, there was some evidence that early session
progress divergence was associated with lower posttreatment worry; however, this
finding was no longer significant when patient- and therapist-rated initial session
progress were in the model. When all three predictors were included, only patientperceived initial session helpfulness predicted posttreatment worry, suggesting that (at
least for posttreatment worry level) initial patient perceptions of session helpfulness are
more predictive of ultimate patient outcome than either therapist initial perceptions or
subsequent early progress convergence/divergence.
Although counter to my prediction, the finding that patients in dyads that diverged
in their session progress ratings tended to evidence a faster subsequent decrease in
distress may actually make intuitive sense when you consider the direction of the
divergence and who is doing the diverging. Descriptive information showed that patients
perceived greater session progress than their therapist at each session in the vast majority
of dyads. Thus, increased session progress discrepancy likely reflected increasing
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positivity in patients’ session progress perceptions over time, which would
understandably relate to their self-reported lower distress (especially if the therapists lack
of similar progress optimism simply reflected the aforementioned “better safe than sorry”
pattern, which has been shown to be clinically beneficial; Atzil-Slonim et al., 2015).
However, future research should directly test (inferentially) the prediction of outcome
from both (a) which dyad member was diverging, and (b) the direction of the discrepancy
(i.e., which dyad member rated session progress more positively).
It is important reiterate, though, that early session progress
convergence/divergence failed to predict most outcomes in this study. There may be
several reasons for this. First, the lack of association may be an artifact of the construct
used in the present study; that is, it may be more important for patients and therapists to
converge on their experience of the session, rather than on their evaluation of its
helpfulness. In fact, this notion could explain the reason that Kivlighan and Arthur (2000)
found that greater patient-therapist convergence in their ratings of important session
events (i.e., experiences within the session) was associated with decreases in
interpersonal problems. Taking it further, the difference between experience and
evaluation also seems consistent with research on existential isolation, or the feeling of
separateness that results from feeling alone in one’s subjective experience (Pinel, Long,
Landau, & Pyszczynski, 2004; Yalom, 1980). People high in existential isolation feel as
though no one truly understands them at their core, an experience that has been shown to
correlate with mental health problems, such as anxiety, depression, alienation, loneliness,
and interpersonal dependency (Costello & Long; 2014). This research suggests that
heightening subjective convergence, what Pinel et al. (2004) have termed “I-sharing,”
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may counteract experiences of existential isolation, promote prosocial behavior, and help
alleviate mental health suffering. In other words, perhaps dyadic convergence only relates
to adaptive relational outcomes when dyads are converging or diverging on their
subjective experiences, but not when they are converging or diverging on more objective
evaluations like session progress. If this were accurate, though further research is
required, it would be important for clinicians to promote experiences of I-sharing
(subjective convergence) in session for which Pinel, Bernecker, and Rampy (2015)
discuss several possible strategies.
A second, but related, plausible reason why early session progress divergence
failed to predict most outcomes in this study could be that session progress is less of a
true dyadic variable than alliance (which did predict most outcomes), so patient-therapist
agreement on progress is less important. Finally, and on a more methodological note, the
failure of session progress convergence/divergence to predict most outcomes could
largely be an artifact of the SPS’s low variability. In fact, recall that low variability in the
session progress convergence/divergence variable restricted this study’s analyses to
focusing on sessions 2-5 (rather than the first half of treatment, as with the alliance).
Thus, future studies should use a different measure of session progress in order to
determine more definitively whether session progress convergence/divergence is
important for patient outcomes.
Even with these limitations in mind, the present study’s exploratory moderator
analyses provide some additional information about the circumstances under which early
session progress convergence/divergence is associated with treatment outcomes.
Although treatment group and therapist-rated initial session progress did not moderate the
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early session progress convergence/divergence-outcome associations, patient-rated initial
session progress did. For dyads in which patients perceived their initial session as more
helpful, progress convergence was associated with a pattern of getting worse before
getting better with regard to distress; for these same types of high progress dyads,
progress divergence was associated with a pattern of getting less distressed quickly then
leveling off. However, both of these combinations resulted in roughly equivalent levels of
patient distress at posttreatment. Thus, it is possible that for patients who initially
perceive a high degree of helpfulness or progress, dyadic convergence may be a marker
for a more challenging treatment period, whereas dyadic divergence may be a marker for
speedier improvement. One reason for this unexpected finding could relate to who is
doing the “converging.” Because this finding was only observed for patients who initially
perceived their session as very helpful, it could be that for these dyads convergence
represents a movement toward their therapists’ more negative perceptions. However, this
notion requires testing.
4.3 Limitations
This study had several notable limitations. First, the creation of the
convergence/divergence variables required that I run a large number of models,
increasing the likelihood of Type I error. Second, the way I created the convergence
variables made it impossible to tell which dyad member is “doing” the converging or
diverging, and whether this matters for outcomes. Third, it is possible that the relatively
small number of therapists in the present study limited my ability to detect therapist
effects both on the convergence/divergence variables and on the treatment outcomes.
Fourth, both of the significant moderator findings were only present for distress outcomes
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(and not replicated for the worry outcome). Finally, the findings currently have limited
generalizability beyond patients with severe GAD receiving a form of CBT or integrative
CBT (though the alliance convergence findings are generally consistent with prior
research on patients with chronic depression; Laws et al., 2016).
4.4 Conclusion
To conclude, the present findings add to the as yet scarce literature in suggesting
that convergence in therapists’ and patients’ ratings of the alliance may be associated
with better psychotherapy outcome (in temporal sequence). This result now holds across
two types of treatment for chronic depression and the present two treatments for GAD;
thus, it may be a common facilitative process worthy of wider investigation and clinical
attention. Such investigation should continue to capitalize on, and attempt to improve,
true dyadic level analysis. Doing this, though, requires assessing the alliance both from
the more traditional individual perspectives (especially given that early patient-rated
alliance served as a moderator in the present analyses), as well as from both patient and
therapist perspectives in parallel across time. With enough replication of results, and the
findings to date do suggest something potentially unique and clinically useful about
longitudinal alliance convergence, this dyadic variable could represent another clinically
vital layer of monitoring and feedback to which clinicians needs to be responsive.
Finally, it may be that convergence/divergence may be most important for truly relational
constructs, such as the alliance, as the present findings were less expansive and
conclusive for session progress convergence/divergence. As noted, though, it may still be
important for patients and therapists to align on subjective experiences within sessions,
but more direct measurement of such alignment (beyond retrospective accounts of
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progress) are likely needed. With such advancements in dyadic level relational process,
researchers can continue to explicate predictors and mechanism of therapeutic change.
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APPENDIX A
MEASURES
Penn State Worry Questionnaire
Enter the number that best describes how typical or characteristic each item is of you,
putting the number next to the item.
1
Not at all
typical

2

3
Somewhat
typical

4

5
Very
typical

1. If I don't have enough time to do everything I don't worry
about it.
2. My worries overwhelm me.
3. I don't tend to worry about things.
4. Many situations make me worry.
5. I know I shouldn't worry about things, but I just can't help
it.
6. When I am under pressure I worry a lot.
7. I am always worrying about something.
8. I find it easy to dismiss worrisome thoughts.
9. As soon as I finish one task, I start to worry about
everything else I have to do.
10. I never worry about anything.
11. When there is nothing more I can do about a concern, I
don't worry about it any more.
12. I've been a worrier all my life.
13. I notice that I have been worrying about things.
14. Once I start worrying, I can't stop.
15. I worry all the time.
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16. I worry about projects until they are all done.
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Depression Anxiety Stress Scales – 21 item version
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the statement applied
to you over the past week. There are no right or wrong answers. Do not spend too much time on any
statement.
The rating scale is as follows:
0
1
2
3

Did not apply to me at all
Applied to me to some degree, or some of the time
Applied to me to a considerable degree, or a good part of time
Applied to me very much, or most of the time

1

I found it hard to wind down

0

1

2

3

2

I was aware of dryness of my mouth

0

1

2

3

3

I couldn’t seem to experience any positive feeling at all

0

1

2

3

4

I experienced breathing difficulty (e.g., excessively rapid breathing,
breathlessness in the absence of physical exertion)

0

1

2

3

5

I found it difficult to work up the initiative to do things

0

1

2

3

6

I tended to over-react to situations

0

1

2

3

7

I experienced trembling (e.g., in the hands)

0

1

2

3

8

I felt that I was using a lot of nervous energy

0

1

2

3

9

I was worried about situations in which I might panic and make a
fool of myself

0

1

2

3

10

I felt that I had nothing to look forward to

0

1

2

3

11

I found myself getting agitated

0

1

2

3

12

I found it difficult to relax

0

1

2

3

13

I felt down-hearted and blue

0

1

2

3

14

I was intolerant of anything that kept me from getting on with what
I was doing

0

1

2

3

15

I felt I was close to panic

0

1

2

3

16

I was unable to become enthusiastic about anything

0

1

2

3

17

I felt I wasn’t worth much as a person

0

1

2

3

18

I felt that I was rather touchy

0

1

2

3

19

I was aware of the action of my heart in the absence of physical
exertion (e.g., sense of heart rate increase, heart missing a beat)

0

1

2

3

20

I felt scared without any good reason

0

1

2

3

21

I felt that life was meaningless

0

1

2

3
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WAI – Patient Version
On the following pages there are some sentences that describe some of the different ways
a person might think or feel about his or her therapist (counselor). Please complete these ratings
in terms of your experience with your therapist during the most recent session. As you read the
sentences, mentally insert the name of your therapist (counselor) in place of the _________ in the
text.

1
Never

2
Rarely

3
4
Occasionally Sometimes

5
Often

6
Very Often

7
Always

Use the above seven point scale for each item. If the statement describes the way you
always feel (or think), circle the number ‘7’; if it never applies to you, circle the number ‘1’. Use
the numbers in between to describe the variations between these extremes. This questionnaire is
confidential; your therapist will not see your answers. Work fast; your first impressions are the
ones we would like to see. Please don’t forget to respond to every item.
______

1. __________ and I agree about the things I will need to do in therapy to help
improve my situation.

______

2. What I am doing in therapy gives me new ways of looking at my problem.

______

3. I believe __________ likes me.

______

4. __________ does not understand what I am trying to accomplish in therapy.

______

5. I am confident in _________’s ability to help me.

______

6. __________ and I are working on mutually agreed upon goals.

______

7. I feel that _________ appreciates me.

______

8. We agree on what is important for me to work on.

______

9. __________ and I trust one another.

______

10. __________ and I have different ideas on what my problems are.

______

11. We have established a good understanding of the kind of changes that would be
good for me.

______

12. I believe the way we are working with my problem is correct.
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Therapist – WAI
Code #:_____

Session:_____

On the following pages there are some sentences that describe some of the different ways
a person might think or feel about his or her client Please complete these ratings in terms of your
experience with your client during this first portion of the session. As you read the sentences,
mentally insert the name of your client in place of the _________ in the text.

1
Never

2
Rarely

3
4
Occasionally Sometimes

5
Often

6
Very Often

7
Always

Use the above seven point scale for each item. If the statement describes the way you
always feel (or think), circle the number ‘7’; if it never applies to you, circle the number ‘1’. Use
the numbers in between to describe the variations between these extremes. Work fast; your first
impressions are the ones we would like to see.
______

1. __________ and I agree about the things I will need to do in therapy to help
improve his/her situation.

______

2. __________ and I both feel confident about the usefulness of our current activity
in therapy.

______

3. I believe __________ likes me.

______

4. I have doubts about what we are trying to accomplish in therapy.

______

5. I am confident in my ability to help __________ .

______

6. We are working on mutually agreed upon goals.

______

7. I appreciate __________ as a person.

______

8. We agree on what is important for __________ to work on.

______

9. __________ and I have built a mutual trust.

______

10. __________ and I have different ideas on what his/her real problems are.

______

11. We have established a good understanding between us of the kind of changes that
would be good for __________.

______

12. __________ believes the way we are working with his/her problem is correct.
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Client Post-Session Impact
1. How do you feel about the session which you have just completed?
(Circle the one answer which best applies.)
THIS SESSION WAS:
1. Perfect
2. Excellent
3. Very good
4. Pretty good
5. Fair
6. Pretty poor
7. Very poor
2. How much progress do you feel you made in dealing with your problems this session?
1. A great deal of progress
2. Considerable progress
3. Moderate progress
4. Some progress
5. Didn’t get anywhere this session
6. In some ways my problems seem to have gotten worse this session
3. How well do you feel that you are getting along, emotionally and psychologically, at this
time?
I AM GETTING ALONG:
1. Very well; much the way I would like to.
2. Quite well; no important complaints
3. Fairly well; have my ups and downs.
4. So-so; manage to keep going with some effort
5. Fairly poor; life gets pretty tough for me at times.
6. Quite poorly; can barely manage to deal with things
4. How helpful do you feel your therapist was to you this session?
1. Completely helpful
2. Very helpful
3. Pretty helpful
4. Somewhat helpful
5. Slightly helpful
6. Not at all helpful
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Therapist Post-Session Impact
1. How do you feel about the session which you have just completed?
(circle the one answer which best applies.)
THIS SESSION WAS:
1. Perfect
2. Excellent
3. Very good
4. Pretty good
5. Fair
6. Pretty poor
7. Very poor
2. How much progress do you feel your client made in dealing with his/her problems this
session?
1. A great deal of progress
2. Considerable progress
3. Moderate progress
4. Some progress
5. Didn’t get anywhere this session
6. In some ways his/her problems seem to have gotten worse this session
3. How well do you feel that your client is getting along, emotionally and psychologically, at
this time?
HE / SHE GETTING ALONG:
1. Very well; much the way he/she would like to.
2. Quite well; no important complaints.
3. Fairly well; he/she has ups and downs.
4. So-so; manages to keep going with some effort
5. Fairly poor; life gets pretty tough for him/her at times.
6. Quite poorly; can barely manage to deal with things
4. How helpful do you feel you were to your client this session?
1. Completely helpful
2. Very helpful
3. Pretty helpful
4. Somewhat helpful
5. Slightly helpful
6. Not at all helpful
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APPENDIX B
TABLES
Table 1
Participant Characteristics at Baseline by Treatment Condition
Variables
Age
Sex*
Female
Male
Race
Caucasian
Asian
Hispanic
Multiracial/other
Annual household income
Less than 25,000
25,000-50,000
50,000-75,000
75,000-100,000
100,000 or more
Education
High school or less
Some college/university
Completed college
Some graduate school
Marital statusa
Single
Cohabiting/married
On medication?*
Yes
No
Outcome variables
PSWQ
DASS
CQ*

M
34.19

75.05
32.59
107.23

CBT (n = 43)
SD
n
11.92

%

MI-CBT (n = 42)
M
SD
n
%
32.45 10.54

41
2

95.34
4.65

34
8

80.95
19.05

32
5
2
4

74.42
11.62
4.65
9.30

31
6
1
4

73.81
14.29
2.38
9.52

10
9
11
8
5

23.26
20.93
25.58
18.60
11.63

6
8
8
6
13

14.29
19.05
19.05
14.29
30.95

4
13
18
8

9.30
30.23
41.86
18.60

2
9
19
12

4.76
21.43
45.24
28.57

19
23

44.19
54.76

18
24

42.86
57.14

14
29

32.56
67.44

6
36

14.29
85.71

3.43
11.84
8.76

74.69
29.19
101.60

3.44
10.76
11.50

Note. M = mean; SD = standard deviation; PSWQ = Penn State Worry Questionnaire;
DASS = Depression Anxiety Stress Scales; CQ = Change Questionnaire.
a
Category sums to less than 43 for the CBT condition due to missing or unreported data.
* Groups differed significantly at baseline on this variable (p < .05; differences described
in text)
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Table 2
Parameter Estimates for Change in Alliance Discrepancy across the Entire Treatment Period and Early in Treatment.
Convergence across
treatmenta
Coefficient
p
(SE)
Fixed effects
Session 2 WAI discrepancy, γ00
Change in WAI discrepancy, γ10
Curvilinear change in WAI
discrepancy, γ20
Variance Components
Session 2 WAI discrepancy, 00
Change in WAI discrepancy, 11
Curvilinear change in WAI
discrepancy, 22
Level 1, σ2
Model fit statistics
Model deviance (df)
Model comparison test

Quadratic convergence
across treatment
Coefficient
p
(SE)

Early alliance
convergenceb
Coefficient
p
(SE)

Early quadratic
convergence
Coefficient
p
(SE)
1.77 (0.07)
-0.13 (0.20)
-0.02 (0.19)

< .001
.512

Estimate
0.31
0.19
0.20

p
< .001
< .50
.45

1.73 (0.07)
-.14 (0.07)
--

< .001
.035
--

1.74 (0.07)
-0.24 (0.20)
0.09 (0.18)

< .001
.25
.61

1.78 (0.07)
-.14 (0.06)
--

< .001
.014

Estimate
0.33
0.13
--

p
< .001
.001
--

Estimate
0.35
0.60
.17

p
< .001
.22
> .50

Estimate
0.34***
0.02†

p
< .001
.08

--

0.15

0.15

0.42

0.17

761.02 (6)

758.25 (10)
χ2(4) = 2.77

810.80 (6)

809.59 (10)
χ2(4) = 1.21

> .50

Note. WAI = Working Alliance Inventory.
a
The models examining convergence across treatment estimated change in alliance discrepancy across even sessions from session 2
through 14.
b
The models examining early convergence estimated change in alliance discrepancy across sessions 2 through 8.
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.94

> .50

Table 3
Parameters for a 3-level Unconditional Model of Early Alliance Discrepancy Change
Early alliance discrepancy change
(session 2-8)
Coefficient (SE)
1.75*** (0.11)
-0.02** (0.13)
Level-2 df = 62
Level-3 df = 20
0.15***
0.0006**
0.16***
0.00003
0.17
782.46 (9)
(not calculated)

Fixed effects
Average session 2 WAI discrepancy, γ000
Average WAI discrepancy change, γ100
Random effects
Level-2 intercept, r0
Level-2 slope, r1
Level-3 intercept, u00
Level-3 slope, u10
Level 1, e
Deviance statistic (parameters)
Improvement in model fit
Note. WAI = Working Alliance Inventory.
* p = .05. ** p < .05. *** p < .001.
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Table 4
Descriptive Statistics and Intercorrelations of Predictors, Moderators, and Covariates for the Alliance Convergence/Divergence
Models

Variable
1. Baseline DASS
2. Baseline PSWQ
3. Treatment conditiona
4. Session 1 patient-rated WAI
5. Session 1 therapist-rated WAI
6. Early WAI convergence/divergence
(sessions 2-8)

M
30.91
74.87
-70.38
61.86
-.14

SD
11.38
3.42
-9.49
9.77
.05

1
–
.36***
.17
.04
.15
.12

2

3

4

5

6

–
.07
.36***
.23*
.04

–
-.04
.28**
-.10

–
.11
-.14

–
.16

–

Note. Sample sizes for the correlations vary due to two people missing alliance convergence data (range = 83-85); DASS =
Depression, Anxiety, and Stress Scale; PSWQ = Penn State Worry Questionnaire; WAI = Working Alliance Inventory
a
Treatment condition was coded as: MI-CBT = -0.5, CBT = 0.5.
*p< .05, **p < .01, ***p = .001.
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Table 5
Early Alliance Convergence as a Predictor of Posttreatment Worry, Subsequent Worry Change, and Subsequent
Acceleration/Deceleration in the Rate of Worry Change
Unconditional model

Early alliance convergence
only model
Coefficient (SE)
p
-11.58 (1.94)
< .001

Early alliance convergence and
covariates model
Coefficient (SE)
p
-11.60 (1.89)
< .001

Coefficient (SE)
-11.58 (1.98)

p
< .001

WAI divergence/convergence, γ01
Baseline PSWQ, γ02
Treatment group, γ03

----

----

74.61 (41.41)
---

.075
---

75.55 (41.67)
0.08 (0.43)
3.44 (4.09)

.074
.851
.403

Therapist session 1 WAI, γ04

--

--

--

--

-0.27 (0.21)

.215

Patient session 1 WAI, γ05

--

--

--

--

-0.38 (0.22)

.094

-18.89 (3.69)

< .001

-19.11 (3.61)

< .001

-19.42 (3.58)

< .001

------

------

168.40 (76.14)
-----

.030
-----

163.33 (77.87)
0.45 (0.82)
-6.44 (7.82)
-0.28 (.40)
-0.14 (.42)

.039
.587
.413
.485
.734

-8.18 (3.08)

.01

-8.41 (3.04)

.007

-8.54 (3.04)

.006

WAI divergence/convergence, γ21

--

--

139.80 (63.93)

.032

138.82 (65.90)

.038

Baseline PSWQ, γ22

--

--

--

--

0.26 (0.70)

.711

Treatment group, γ23

--

--

--

--

-5.50 (6.64)

.410

Therapist session 1 WAI, γ24

--

--

--

--

-0.16 (0.34)

.636

Patient session 1 WAI, γ125

--

--

--

--

0.05 (0.34)

.878

Variance component
293.58
335.60
70.37
39.64
3683.44 (10)

p
< .001
.007
.291
---

Variance component
281.85
294.19
53.74
39.25
3676.84 (13)

p
< .001
.017
.396
---

Variance component
264.65
267.10
45.57
39.18
3669.28 (25)

p
< .001
.014
.320
---

Fixed Effects
Posttreatment PSWQ (intercept), γ00

Change in PSWQ (slope), γ10
WAI divergence/convergence, γ11
Baseline PSWQ, γ12
Treatment group, γ13
Therapist session 1 WAI, γ14
Patient session 1 WAI, γ15
Rate of acceleration/deceleration (curvature), γ20

Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Note. PSWQ = Penn State Worry Questionnaire; WAI = Working Alliance Inventory
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Table 6
Patient Session 1 Alliance by Early Alliance Convergence as a Predictor of Posttreatment Worry, Subsequent Worry Change,
and Subsequent Acceleration/Deceleration in the Rate of Worry Change
Fixed effects
Posttreatment PSWQ (intercept), γ00
WAI divergence/convergence, γ01
Baseline PSWQ, γ02
Patient session 1 WAI, γ03
Patient session 1 WAI by convergence, γ04
Change in PSWQ (slope), γ10
WAI divergence/convergence, γ11
Baseline PSWQ, γ12
Patient session 1 WAI, γ13
Patient session 1 WAI by convergence, γ14
Rate of acceleration/deceleration (curvature), γ20

Main effects and covariate model
Coefficient (SE)
p
-11.59 (1.91)
< .001

Interaction model
Coefficient (SE)
p
-11.84 (1.92)
< .001

64.64 (41.28)
-0.03 (0.43)
-0.35 (0.22)

.12
.94
.12

53.05 (43.05)
-0.04 (0.43)
-0.39 (0.22)

.22
.94
.09

--

--

-3.99 (4.43)

.37

-19.12 (3.61)

< .001

-18.69 (3.68)

< .001

160.49 (77.31)
0.32 (0.81)
-0.24 (0.41)
--

.04
.69
.57
--

177.09 (83.57)
0.32 (0.82)
-0.20 (0.42)
3.52 (8.28)

.04
.70
.64
.67

-8.34 (3.04)

.008

-7.57 (3.09)

.02

138.74 (65.08)

.04

169.88 (70.29)

.02

Baseline PSWQ, γ22

0.32 (0.81)

.69

0.18 (0.69)

.79

Patient session 1 WAI, γ23

-0.02 (0.35)

.95

0.06 (0.35)

.87

--

--

7.68 (6.93)

.27

WAI divergence/convergence, γ21

Patient session 1 WAI by convergence, γ24

Variance component
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

270.53
288.98
53.41
39.26
3673.22 (19)

Variance component
p
< .001
.01
.34
---

267.77
304.70
59.39
39.08
3669.55 (22)

Note. PSWQ = Penn State Worry Questionnaire; WAI= Working Alliance Inventory.
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p
< .001
.01
.33
---

Table 7
Therapist Session 1 Alliance by Early Alliance Convergence as a Predictor of Posttreatment Worry, Subsequent Worry
Change, and Subsequent Acceleration/Deceleration in the Rate of Worry Change

Fixed effects
Posttreatment PSWQ (intercept), γ00
WAI divergence/convergence, γ01
Baseline PSWQ, γ02
Therapist session 1 WAI, γ03
Therapist session 1 WAI by convergence, γ04
Change in PSWQ (slope), γ10
WAI divergence/convergence, γ11
Baseline PSWQ, γ12
Therapist session 1 WAI, γ13
Therapist session 1 WAI by convergence, γ14
Rate of acceleration/deceleration (curvature), γ20

Main effects and covariate model
Coefficient (SE)
p
-11.58 (1.92)
< .001

Interaction model
Coefficient (SE)
p
-11.43 (1.95)
< .001

82.91 (41.52)
-0.18 (0.41)
-0.23 (0.21)

.05
.67
.27

82.75 (41.47)
-0.14 (0.42)
-0.23 (0.21)

.05
.75
.26

--

--

-2.11 (4.66)

.65

-19.06 (3.60)

< .001

-18.39 (3.60)

< .001

0.35 (0.76)
0.35 (0.76)
-0.40 (0.38)
--

.65
.65
.30
--

177.89 (75.73)
0.59 (0.77)
-0.41 (0.38)
-11.02 (8.43)

.02
.44
.29
.20

-8.37 (3.03)

.007

-7.96 (3.05)

.01

146.54 (64.45)

.03

145.39 (64.15)

.03

Baseline PSWQ, γ22

0.31 (0.64)

.63

0.46 (0.65)

.48

Therapist session 1 WAI, γ23

-0.26 (0.32)

.43

-0.26 (0.32)

.42

--

--

-6.77 (7.14)

.35

Variance component
275.51
284.18
50.70
39.21
3674.34 (19)

p
<.001
.01
.35
---

Variance component
274.81
263.67
44.76
39.17
3672.16 (22)

p
<.001
.02
.35
---

WAI divergence/convergence, γ21

Therapist session 1 WAI by convergence, γ24
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Note. PSWQ = Penn State Worry Questionnaire; WAI= Working Alliance Inventory.
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Table 8
Treatment Condition by Early Alliance Convergence as a Predictor of Posttreatment Worry, Subsequent Worry Change, and
Subsequent Acceleration/Deceleration in the Rate of Worry Change
Fixed Effects
Posttreatment PSWQ (intercept), γ00
WAI divergence/convergence, γ01
Baseline PSWQ, γ02
Treatmenta, γ03
Treatment by convergence, γ04
Change in PSWQ (slope), γ10
WAI divergence/convergence, γ11
Baseline PSWQ, γ12
Treatment, γ13
Treatment by convergence, γ14
Rate of acceleration/deceleration (curvature), γ20

Main effects and covariate model
Coefficient (SE)
p
-11.58 (1.94)
< .001
76.14 (41.53)
-0.28 (0.41)
0.42 (3.90)

Interaction model
Coefficient (SE)
p
-11.70 (1.94)
< .001

.07
.67
.92

69.12 (43.20)
-0.25 (0.41)
0.33 (3.90)

.11
.55
.93

--

--

-50.46 (87.15)

.56

-19.59 (3.56)

< .001

-20.39 (3.56)

< .001

156.54 (75.55)
0.26 (0.73)
-8.73 (7.21)
--

.04
.73
.23
--

108.13 (82.12)
0.45 (0.73)
-9.66 (7.15)
-236.81 (165.83)

.19
.54
.18
.16

-8.75 (3.02)

.005

-9.16 (3.04)

.003

130.93 (63.97)

.04

105.35 (70.57)

.14

Baseline PSWQ, γ22

0.26 (0.62)

.68

0.36 (0.62)

.57

Treatment, γ23

-6.34 (0.30)

.30

-6.82 (6.12)

.27

--

--

-123.83 (142.52)

.39

Variance component
280.15
265.24
44.71
39.16
3673.97 (19)

p
< .001
.02
.38
---

Variance component
279.24
241.32
38.27
39.19
3670.59 (22)

p
< .001
.03
.38
---

WAI divergence/convergence, γ21

Treatment by convergence, γ24
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Note. PSWQ = Penn State Worry Questionnaire; WAI= Working Alliance Inventory.
a
Treatment group was dummy coded CBT = 0.5, MI-CBT = -0.5.
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Table 9
Early Alliance Convergence as a Predictor of Posttreatment Distress and Subsequent Distress Change
Unconditional model
Fixed Effects
Posttreatment DASS (intercept), γ00
WAI divergence/convergence, γ01
Baseline DASS, γ02
Treatment group, γ03
Therapist session 1 WAI, γ04
Patient session 1 WAI, γ05
Change in DASS (slope), γ10
WAI divergence/convergence, γ11
Baseline DASS, γ12
Treatment group, γ13
Therapist session 1 WAI, γ14
Patient session 1 WAI, γ15
Random effects
DASS intercept, 00
DASS slope, 11
Level 1, σ2
Model deviance (df)

Coefficient (SE)
-3.79 (1.19)
------5.33 (1.32)
-----Variance component
98.28
72.59
29.94
1642.54

p
.002
-----<.001
-----p
< .001
< .001
---

Early alliance convergence
only model
Coefficient (SE)
p
-3.80 (1.15)
< .001
60.96 (24.50)
.015
---------5.49 (1.25)
< .001
69.83 (26.42)
.010
--------Variance component
p
89.64
< .001
59.61
< .001
30.06
-1633.16 (8)
--

Note. DASS = Depression, Anxiety, and Stress Scale; WAI= Working Alliance Inventory.
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Early alliance convergence and
covariates model
Coefficient (SE)
p
-3.83 (1.04)
< .001
53.17 (23.13)
.024
0.29 (0.09)
.002
1.48 (2.28)
.518
-0.21 (0.12)
.077
-0.26 (0.12)
.026
-5.26 (1.20)
< .001
78.44 (26.28)
.004
-0.23 (0.11)
.041
0.85 (2.65)
.751
-0.14 (0.13)
.281
-0.05 (0.13)
.712
Variance component
p
70.15
< .001
50.34
< .001
30.10
-1605.12 (16)
--

Table 10
Patient Session 1 Alliance by Early Alliance Convergence as a Predictor of Posttreatment Distress and Subsequent Distress
Change

Fixed Effects
Posttreatment DASS (intercept), γ00
WAI divergence/convergence, γ01
Baseline DASS, γ02
Patient session 1 WAI, γ03
Patient session 1 WAI by Convergence, γ04
Change in DASS (slope), γ10
WAI divergence/convergence, γ11
Baseline DASS, γ12
Patient session 1 WAI, γ13
Patient session 1 WAI by Convergence, γ14
Random effects
DASS intercept, 00
DASS slope, 11
Level 1, σ2
Model deviance (df)

Main effects and covariate
model
Coefficient (SE)
p
-3.83 (1.06)
< .001
44.96 (23.05)
.06
0.28 (0.09)
.003
-0.27 (0.11)
.02
---5.29 (1.20)
< .001
73.03 (25.86)
.006
-0.24 (0.11)
.03
-0.05 (0.13)
.67
--Variance component
p
73.49
< .001
51.62
< .001
30.16
-1608.49 (12)
--

Interaction model
Coefficient (SE)
-4.11 (1.05)
32.42 (23.78)
0.28 (0.09)
-0.31 (0.11)
-4.15 (2.43)
-5.79 (1.18)
53.77 (26.90)
-0.24 (0.10)
-0.11 (0.12)
-5.43 (2.66)
Variance component
69.91
44.00
30.29
1603.53 (14)

Note. WAI= Working Alliance Inventory; DASS = Depression, Anxiety, and Stress Scale.
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p
< .001
.18
.002
.008
.09
< .001
.049
.02
.38
.04
p
< .001
< .001
---

Table 11
Therapist Session 1 Alliance by Early Alliance Convergence as a Predictor of Posttreatment Distress and Subsequent Distress
Change

Fixed Effects
Posttreatment DASS (intercept), γ00
WAI divergence/convergence, γ01
Baseline DASS, γ02
Therapist session 1 WAI, γ03
Therapist session 1 WAI by convergence, γ04
Change in DASS (slope), γ10
Alliance divergence/convergence, γ11
Baseline DASS, γ12
Therapist session 1 WAI, γ13
Therapist session 1 WAI by convergence, γ14
Random effects
DASS intercept, 00
DASS slope, 11
Level 1, σ2
Model deviance (df)

Main effects and covariate
model
Coefficient (SE)
p
-3.81 (1.08)
< .001
59.54 (23.35)
.01
0.29 (0.09)
.003
-0.22 (0.11)
.06
---5.34 (1.20)
< .001
78.45 (25.54)
.003
-0.22 (0.11)
.04
-0.14 (0.13)
.28
--Variance component
p
76.27
50.18
29.95
1608.49 (12)

< .001
< .001
---

Interaction model
Coefficient (SE)
-3.59 (1.08)
58.90 (23.13)
0.31 (0.09)
-0.22 (0.11)
-3.13 (2.55)
-5.17 (1.20)
77.82 (25.33)
-0.21 (0.11)
-0.13 (0.13)
-2.84 (2.75)
Variance
component
74.41
48.28
29.99
1608.64 (14)

Note. WAI= Working Alliance Inventory; DASS = Depression, Anxiety, and Stress Scale.
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p
< .001
.01
.002
.06
.22
< .001
.003
.06
.30
.31
p
< .001
< .001
---

Table 12
Treatment Condition by Early Alliance Convergence as a Predictor of Posttreatment Distress and Subsequent Distress Change

Fixed Effects
Posttreatment DASS (intercept), γ00
WAI divergence/convergence, γ01
Baseline DASS, γ02
Treatment, γ03
Treatment by convergence, γ04
Change in DASS (slope), γ10
Alliance divergence/convergence, γ11
Baseline DASS, γ12
Treatment, γ13
Treatment by convergence, γ14
Random effects
DASS intercept, 00
DASS slope, 11
Level 1, σ2
Model deviance (df)

Main effects and covariate
model
Coefficient (SE)
p
-3.81 (1.10)
< .001
52.04 (23.75)
.03
0.27 (0.10)
.006
-0.85 (2.25)
.71
---5.34 (1.21)
< .001
74.36 (25.74)
.005
-0.24 (0.11)
.03
-0.19 (2.48)
.94
--Variance component
p
80.15
< .001
51.54
< .001
30.01
-1614.07 (12)
--

Interaction model
Coefficient (SE)
p
-3.87 (1.10)
< .001
48.21 (24.65)
.05
0.27 (0.10)
.006
-0.88 (2.24)
.70
-27.73 (48.96)
.57
-5.55 (1.20)
< .001
62.11 (27.72)
.03
-0.25 (0.11)
.02
-0.33 (2.46)
.90
-63.42 (55.34)
.26
Variance component
p
79.70
< .001
48.97
< .001
30.03
-1612.76 (14)
--

Note. WAI= Working Alliance Inventory; DASS = Depression, Anxiety, and Stress Scale
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Table 13
Parameter Estimates for Change in Session Progress Discrepancy across the Entire Treatment Period and Early in Treatment.

Fixed effects
Session 2 SPS discrepancy, γ00
Change in SPS discrepancy, γ10
Curvilinear change in SPS
discrepancy, γ20
Random effects
Session 2 SPS discrepancy, 00
Change in SPS discrepancy, 11
Curvilinear change in SPS
discrepancy, 22
Level 1, σ2
Model fit statistics
Model deviance (df)
Model comparison test

Convergence across
treatmenta
Coefficient
(SE)
p
1.22 (0.06) < .001
.14 (0.07)
.031
--Variance
component
0.25
0.08
--

Quadratic convergence
across treatment
Coefficient
(SE)
p
1.20 (0.07)
< .001
0.36 (0.21)
.085
-0.22 (0.20)
.28

< .001
.054
--

Variance
component
0.22
0.19
.19

0.19

--

819.10 (6)
--

---

p

Early convergenceb
Coefficient
(SE)
p
1.20 (0.06)
< .001
.20 (0.07)
.008
---

< .001
> .50
> .50

Variance
component
0.22
0.13
--

< .001
.008
--

0.18

--

0.16

--

815.76 (10)
χ2(4) = 3.34

-> .50

523.92 (6)
--

---

p

P

Note. SPS = Session Progress Scale.
a
The models examining convergence across treatment estimated change in session progress discrepancy across even sessions
from session 2 through 14.
b
The models examining early convergence estimated change in session progress discrepancy across sessions 2 through 5.
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Table 14
Parameters for a 3-level Unconditional Model of Early Session Progress Discrepancy
Change.

Fixed effects
Average S2 SPS discrepancy, γ000
Average SPS discrepancy change, γ100

Early discrepancy change (session 2-5)
Unstandardized coefficient (SE)
1.16 (0.07)***
0.07 (0.07)
Level-2 df = 61
Level-3 df = 19
0.16***
0.21***
0.02
0.007
0.20
571.99 (9)
(not calculated)

Random effects
Level-2 intercept, r0
Level-2 slope, r1
Level-3 intercept, u00
Level-3 slope, u10
Level 1, e
Deviance statistic (parameters)
Improvement in model fit
Note. SPS = Session Progress Scale.
* p < .05. ** p < .05. *** p < .001.
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Table 15
Descriptive Statistics and Intercorrelations of Predictors, Moderators, and Covariates for Session Progress
Convergence/Divergence Models

Variable
1. Baseline DASS
2. Baseline PSWQ
3. Treatment conditiona
4. Session 1 patient-rated SPS
5. Session 1 therapist-rated SPS
6. Early SPS convergence/divergence
(sessions 2-5)

M
30.91
74.87
-12.08
15.19
.20

SD
11.38
3.42
-3.04
2.08
.23

1
–
.36**
.17
.15
.06
.07

2
–
.07
-.23*
-.19
.06

3

4

–
.11
-.30**
-.21

–
-.03
-.43***

5

–
.11

6

–

Note. Sample sizes for the correlations vary due to two people missing session progress convergence data (range = 83-85);
DASS = Depression, Anxiety, and Stress Scale; PSWQ = Penn State Worry Questionnaire; SPS = Session Progress Scale.
a
Treatment condition was coded as: MI-CBT = -0.5, CBT = 0.5.
*p< .05, **p < .01, ***p < .001.
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Table 16
Early Session Progress Convergence as a Predictor of Posttreatment Worry, Subsequent Worry Change, and Subsequent
Acceleration/Deceleration in the Rate of Worry Change
Fixed Effects
Posttreatment PSWQ (intercept), γ00

Unconditional model
Coefficient (SE)
p
-11.02 (1.92)
< .001

Early convergence only model
Coefficient (SE)
p
-11.01 (1.88)
< .001

Early convergence and covariates model
Coefficient (SE)
p
-11.01 (1.80)
< .001

SPS divergence/convergence, γ01
Baseline PSWQ, γ02
Treatment group, γ03

----

----

-16.11 (8.10)
---

.05
---

-8.99 (8.74)
0.16 (0.39)
-0.78 (3.83)

.31
.69
.84

Therapist session 1 SPS, γ04

--

--

--

--

1.28 (0.94)

.18

Patient session 1 SPS, γ05

--

--

--

--

1.62 (0.69)

.02

-20.71 (4.17)

< .001

-20.79 (4.17)

< .001

-20.91 (4.05)

< .001

------

------

2.01 (17.65)
-----

.91
-----

-7.15 (19.08)
1.17 (0.89)
-9.95 (8.63)
2.41 (2.22)
-0.18 (1.51)

.71
.19
.25
.28
.91

-5.44 (3.74)

.15

-5.52 (3.72)

.14

-5.92 (3.59)

.10

--

--

14.05 (15.75)

.38

6.71 (16.82)

.69

Baseline PSWQ, γ22

--

--

--

--

1.65 (0.79)

.04

Treatment group, γ23

--

--

--

--

-9.54 (7.64)

.22

Therapist session 1 SPS, γ24

--

--

--

--

1.41 (1.99)

.48

Patient session 1 SPS, γ125

--

--

--

--

0.03 (1.33)

.99

Variance component
279.05
729.52
496.58
40.55
5211.44 (10)

p
< .001
< .001
< .001
---

Variance component
265.37
726.21
484.74
40.55
5206.52 (13)

p
< .001
< .001
< .001
---

Variance component
240.31
642.05
401.76
40.55
5175.78 (25)

p
< .001
< .001
< .001
---

Change in PSWQ (slope), γ10
SPS divergence/convergence, γ11
Baseline PSWQ, γ12
Treatment group, γ13
Therapist session 1 SPS, γ14
Patient session 1 SPS, γ15
Rate of acceleration/deceleration (curvature),
γ20
SPS divergence/convergence, γ21

Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Note. PSWQ = Penn State Worry Questionnaire; SPS = Session Progress Scale.
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Table 17
Patient-Rated Session 1 Progress by Early Session Progress Convergence as a Predictor of Posttreatment Worry, Subsequent
Worry Change, and Subsequent Acceleration/Deceleration in the Rate of Worry Change

Fixed Effects
Posttreatment PSWQ (intercept), γ00
SPS divergence/convergence, γ01
Baseline PSWQ, γ02
Patient session 1 SPS, γ03
Patient session 1 SPS by convergence, γ04
Change in PSWQ (slope), γ10
SPS divergence/convergence, γ11
Baseline PSWQ, γ12
Patient session 1 SPS, γ13
Patient session 1 SPS by convergence, γ14
Rate of acceleration/deceleration (curvature), γ20
SPS divergence/convergence, γ21
Baseline PSWQ, γ22
Patient session 1 SPS, γ23
Patient session 1 SPS by convergence, γ24
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Main effects and covariate
model
Coefficient (SE)
p
-11.03 (1.82)
< .001
-7.36 (8.71)
.40
0.03 (0.39)
.93
1.59 (0.70)
.03
---20.64 (4.13)
< .001
-1.73 (19.29)
.93
0.77 (0.88)
.38
-0.41 (1.55)
.79
---5.63 (3.62)
.125
10.92 (16.86)
.52
1.35 (0.77)
.08
-0.19 (1.35)
.89
--Variance component
p
247.37
< .001
707.86
< .001
434.07
< .001
40.58
-5180.62 (19)
--

Note. PSWQ = Penn State Worry Questionnaire; SPS = Session Progress Scale.
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Interaction model
Coefficient (SE)
p
-11.02 (2.02)
< .001
-7.35 (8.71)
.40
0.04 (0.40)
.93
1.59 (0.71)
.03
.03 (2.94)
.99
-22.28 (4.53)
< .001
-3.17 (19.24)
.87
0.69 (0.88)
.44
-0.16 (1.56)
.92
-5.69 (6.50)
.38
-7.42 (3.96)
.07
9.40 (16.78)
.58
1.26 (0.77)
.11
0.09 (1.36)
.95
-6.17 (5.67)
.28
Variance component
p
247.33
< .001
695.29
< .001
419.85
< .001
40.57
-5179.26 (22)
--

Table 18
Therapist-Rated Session 1 Progress by Early Session Progress Convergence as a Predictor of Posttreatment Worry, Subsequent
Worry Change, and Subsequent Acceleration/Deceleration in the Rate of Worry Change

Fixed Effects
Posttreatment PSWQ (intercept), γ00
SPS divergence/convergence, γ01
Baseline PSWQ, γ02
Therapist session 1 SPS, γ03
Therapist session 1 SPS by Convergence, γ04
Change in PSWQ (slope), γ10
SPS divergence/convergence, γ11
Baseline PSWQ, γ12
Therapist session 1 SPS, γ13
Therapist session 1 SPS by Convergence, γ14
Rate of acceleration/deceleration (curvature), γ20
SPS divergence/convergence, γ21
Baseline PSWQ, γ22
Therapist session 1 SPS, γ23
Therapist session 1 SPS by Convergence, γ24
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Main effects and covariate
model
Coefficient (SE)
P
-11.01 (1.85)
< .001
-17.32 (8.09)
.04
-0.05 (0.40)
.90
1.29 (0.93)
.17
---20.57 (4.09)
< .001
-4.13 (17.63)
.82
1.19 (0.86)
.17
3.18 (2.14)
.14
---5.40 (3.61)
.14
8.46 (15.59)
.59
1.61 (0.76)
.04
2.16 (1.91)
.26
--Variance component
P
258.15
< .001
673.05
< .001
420.12
< .001
40.56
-5195.66 (19)
--

Note. SPS = PSWQ = Penn State Worry Questionnaire; Session Progress Scale.
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Interaction model
Coefficient (SE)
p
-11.03 (1.86)
< .001
-17.51 (8.27)
.04
-0.05 (0.40)
.90
1.31 (0.95)
.17
0.43 (3.75)
.91
-20.41 (4.13)
< .001
-3.89 (17.87)
.83
1.22 (0.86)
.16
3.20 (2.15)
.14
-1.54 (8.14)
.85
-5.17 (3.65)
.16
9.21 (15.73)
.56
1.63 (0.76)
.04
2.12 (1.91)
.37
-2.72 (7.17)
.71
Variance component
p
< .001
258.04
< .001
673.88
<.001
418.17
40.56
-5195.25 (22)
--

Table 19
Treatment Condition by Early Session Progress Convergence as a Predictor of Posttreatment Worry, Subsequent Worry
Change, and Subsequent Acceleration/Deceleration in the Rate of Worry Change
Fixed Effects
Posttreatment PSWQ (intercept), γ00
SPS divergence/convergence, γ01
Baseline PSWQ, γ02
Treatmenta, γ03
Treatment by convergence, γ04
Change in PSWQ (slope), γ10
SPS divergence/convergence, γ11
Baseline PSWQ, γ12
Treatment, γ13
Treatment by Convergence, γ14
Rate of acceleration/deceleration (curvature), γ20

Main effects and covariate model
Coefficient (SE)
p
-11.01 (1.87)
< .001
-16.70 (8.28)
-0.15 (0.39)
-1.81 (3.84)

Interaction model
Coefficient (SE)
p
-11.38 (1.91)
< .001

.05
.71
.64

-18.07 (8.39)
-0.20 (0.40)
-1.89 (3.82)

.03
.62
.62

--

--

-15.19 (16.93)

.37

-21.28 (4.05)

< .001

-21.51 (4.10)

< .001

-4.13 (17.44)
1.04 (0.83)
-12.99 (8.26)
--

.81
.22
.12
--

-5.46 (18.05)
1.00 (0.84)
-12.98 (8.26)
-11.70 (36.51)

.76
.24
.12
.75

-6.09 (3.58)

.09

-6.18 (3.62)

.09

SPS divergence/convergence, γ21

8.16 (15.36)

.60

7.29 (15.98)

.65

Baseline PSWQ, γ22

1.53 (0.73)

.04

1.51 (0.74)

.05

-11.09 (7.28)

.13

-11.05 (7.28)

.13

--

--

-6.05 (32.32)

.85

Variance component
263.69
651.00
405.60
40.57
5196.27 (19)

p
< .001
< .001
< .001
---

Variance component
260.92
650.99
405.41
40.56
5195.17 (22)

p
< .001
< .001
< .001
---

Treatment, γ23
Treatment by Convergence, γ24
Random effects
PSWQ intercept, 00
PSWQ slope, 11
PSWQ curvature, 22
Level 1, σ2
Model deviance (df)

Note. PSWQ = Penn State Worry Questionnaire; SPS = Session Progress Scale.
a
Treatment group was dummy coded so that CBT = 0.5, MI-CBT = -0.5.
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Table 20
Early Session Progress Convergence as a Predictor of Posttreatment Distress, Subsequent Distress Change, and Subsequent
Acceleration/Deceleration in the Rate of Distress Change
Unconditional model

Early convergence only model

Early convergence and covariates
model
Coefficient (SE)
p
-3.79 (1.10)
< .001

Coefficient (SE)
-3.79 (1.20)

p
.002

Coefficient (SE)
-3.79 (1.20)

p
.002

SPS divergence/convergence, γ01
Baseline DASS, γ02
Treatment group, γ03

----

----

-1.04 (5.19)
---

.84
---

1.69 (5.43)
0.26 (0.10)
-0.98 (2.40)

.76
.01
.68

Therapist session 1 SPS, γ04

--

--

--

--

0.80 (0.57)

.16

Patient session 1 SPS, γ05

--

--

--

--

0.88 (0.42)

.04

-9.51 (4.58)

.04

-10.16 (4.51)

.03

-10.31 (4.43)

.02

------

------

24.72 (19.14)
-----

.20
-----

29.49 (21.54)
-0.45 (0.41)
-10.31 (9.67)
-2.16 (2.38)
0.13 (1.60)

.18
.28
.29
.37
.94

-0.40 (4.50)

.93

-1.11 (4.35)

.80

-1.57 (4.29)

.72

SPS divergence/convergence, γ21

--

--

40.09 (18.43)

.03

44.52 (20.77)

.04

Baseline DASS, γ22

--

--

--

--

-0.17 (0.40)

.67

Treatment group, γ23

--

--

--

--

-13.91 (9.39)

.14

Therapist session 1 SPS, γ24

--

--

--

--

-3.46 (2.32)

.14

Patient session 1 SPS, γ125

--

--

--

--

0.27 (1.54)

.86

Variance component
94.83
626.64
598.95
34.09
5211.44 (10)

p
< .001
< .001
< .001
---

Variance component
94.93
575.53
501.35
34.05
5206.52 (13)

p
< .001
.001
.001
---

Variance component
74.76
516.63
448.76
33.98
2153.03 (25)

p
< .001
.001
.001
---

Fixed Effects
Posttreatment DASS (intercept), γ00

Change in DASS (slope), γ10
SPS divergence/convergence, γ11
Baseline DASS, γ12
Treatment group, γ13
Therapist session 1 SPS, γ14
Patient session 1 SPS, γ15
Rate of acceleration/deceleration (curvature), γ20

Random effects
DASS intercept, 00
DASS slope, 11
DASS curvature, 22
Level 1, σ2
Model deviance (df)

Note. DASS = Depression Anxiety and Stress Scale; SPS = Session Progress Scale.
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Table 21
Patient Session 1 Progress by Early Session Progress Convergence as a Predictor of Posttreatment Distress, Subsequent
Distress Change, and Subsequent Acceleration/Deceleration in the Rate of Distress Change

Fixed Effects
Posttreatment DASS (intercept), γ00
SPS divergence/convergence, γ01
Baseline DASS, γ02
Patient session 1 SPS, γ03
Patient session 1 SPS by Convergence, γ04
Change in DASS (slope), γ10
SPS divergence/convergence, γ11
Baseline DASS, γ12
Patient session 1 SPS, γ13
Patient session 1 SPS by Convergence, γ14
Rate of acceleration/deceleration (curvature), γ20
SPS divergence/convergence, γ21
Baseline DASS, γ22
Patient session 1 SPS, γ23
Patient session 1 SPS by Convergence, γ24
Random effects
DASS intercept, 00
DASS slope, 11
DASS curvature, 22
Level 1, σ2
Model deviance (df)

Main effects and covariate
model
Coefficient (SE)
p
-3.81 (1.11)
< .001
3.01 (5.39)
.56
0.25 (0.10)
.01
0.89 (0.42)
.04
---9.59 (4.46)
.03
29.31 (21.30)
.17
-0.51 (0.41)
.21
0.13 (1.62)
.93
---0.78 (4.34)
.86
44.58 (20.68)
.03
-0.29 (0.40)
.47
0.25 (1.57)
.88
--Variance component
p
< .001
77.81
< .001
549.38
< .001
499.74
34.05
-2161.69 (19)
--

Note. DASS = Depression, Anxiety, and Stress Scale; SPS = Session Progress Scale.
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Interaction model
Coefficient (SE)
p
-3.70 (1.23)
.004
3.02 (5.39)
.58
0.26 (0.10)
.01
0.87 (0.43)
.05
.36 (1.79)
.84
-13.39 (4.76)
.006
26.31 (20.74)
.21
-0.55 (0.40)
.17
0.85 (1.62)
.60
-13.02 (6.83)
.06
-5.34 (4.59)
.25
41.65 (19.92)
.04
-0.35 (0.38)
.36
1.08 (1.55)
.49
-15.28 (6.56)
.02
Variance component
p
< .001
77.73
.003
470.47
.003
396.37
34.05
-2155.90 (22)
--

Table 22
Therapist Session 1 Progress by Early Session Progress Convergence as a Predictor of Posttreatment Distress, Subsequent
Distress Change, and Subsequent Acceleration/Deceleration in the Rate of Distress Change

Fixed Effects
Posttreatment DASS (intercept), γ00
SPS divergence/convergence, γ01
Baseline DASS, γ02
Therapist session 1 SPS, γ03
Therapist session 1 SPS by Convergence, γ04
Change in DASS (slope), γ10
SPS divergence/convergence, γ11
Baseline DASS, γ12
Therapist session 1 SPS, γ13
Therapist session 1 SPS by Convergence, γ14
Rate of acceleration/deceleration (curvature), γ20
SPS divergence/convergence, γ21
Baseline DASS, γ22
Therapist session 1 SPS, γ23
Therapist session 1 SPS by Convergence, γ24
Random effects
DASS intercept, 00
DASS slope, 11
DASS curvature, 22
Level 1, σ2
Model deviance (df)

Main effects and covariate model
Coefficient (SE)
p
-3.78 (1.13)
.001
-2.95 (4.91)
.55
0.29 (0.10)
.004
0.89 (0.56)
.12
---10.10 (4.44)
.03
31.71 (19.42)
.11
-0.54 (0.40)
.18
-1.31 (2.27)
.57
---1.18 (4.32)
.79
47.25 (18.85)
.01
-0.30 (0.39)
.44
-2.31 (2.21)
.30
--Variance component
p
< .001
80.48
.001
531.60
.001
480.78
33.92
-2166.83 (19)
--

Note. DASS = Depression, Anxiety, and Stress Scale; SPS = Session Progress Scale.
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Interaction model
Coefficient (SE)
p
-3.72 (1.13)
.002
-2.39 (5.02)
.63
0.28 (0.10)
.005
0.84 (0.57)
.15
-1.18 (2.28)
.61
-10.01 (4.49)
.03
32.55 (19.63)
.10
-0.55 (0.40)
.17
-1.39 (2.28)
.54
-1.80 (8.81)
.84
-1.20 (4.37)
.79
47.09 (19.04)
.02
-0.30 (0.39)
.44
-2.29 (2.22)
.31
0.30 (8.54)
.97
Variance component
p
< .001
80.10
.003
530.32
.003
480.43
33.92
-2166.32 (22)
--

Table 23
Treatment Condition by Early Session Progress Convergence as a Predictor of Posttreatment Distress, Subsequent Distress
Change, and Subsequent Acceleration/Deceleration in the Rate of Distress Change

Fixed Effects
Posttreatment DASS (intercept), γ00
SPS divergence/convergence, γ01
Baseline DASS, γ02
Treatmenta, γ03
Treatment by Convergence, γ04
Change in DASS (slope), γ10
SPS divergence/convergence, γ11
Baseline DASS, γ12
Treatment, γ13
Treatment by Convergence, γ14
Rate of acceleration/deceleration (curvature), γ20
SPS divergence/convergence, γ21
Baseline DASS, γ22
Treatment, γ23
Treatment by Convergence, γ24
Random effects
DASS intercept, 00
DASS slope, 11
DASS curvature, 22
Level 1, σ2
Model deviance (df)

Main effects and covariate model
Coefficient (SE)
p
-3.78 (1.14)
.001
-3.04 (5.05)
.55
0.31 (0.10)
.003
-2.06 (2.37)
.39
---9.95 (4.43)
.03
25.81 (19.44)
.19
-0.44 (0.41)
.29
-7.41 (9.21)
.42
---1.11 (4.32)
.80
39.48 (18.87)
.04
-0.18 (0.40)
.66
-9.25 (8.99)
.31
--Variance component
p
< .001
82.56
.001
530.38
.001
481.66
33.98
-2167.61 (19)
--

Note. SPS = Session Progress Scale; DASS = Depression, Anxiety, and Stress Scale.
a
Treatment group was dummy coded so that CBT = 0.5, MI-CBT = -0.5.
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Interaction model
Coefficient (SE)
p
-3.84 (1.16)
.001
-3.23 (5.15)
.53
0.31 (0.10)
.003
-2.08 (2.37)
.39
-2.08 (10.24)
.84
-9.26 (4.41)
.04
33.92 (20.02)
.09
-0.46 (0.40)
.26
-7.51 (9.07)
.54
50.83 (39.22)
.20
-0.84 (4.33)
.85
45.90 (19.61)
.02
-0.21 (0.40)
.61
-9.47 (8.92)
.29
34.36 (38.39)
.37
Variance component
p
< .001
82.45
.002
484.68
.001
461.90
33.99
-2162.21 (22)
--

APPENDIX C
FIGURES
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Figure 1. Differences between patient-therapist alliance scores across treatment.
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Figure 2. Panel A shows the average change in alliance discrepancy across treatment and Panel B depicts the variability around
the average rate of change in discrepancy across treatment for a random sample (n = 41).
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Figure 3. Panel A shows the average change in alliance discrepancy across the first half of treatment and Panel B depicts the
variability around the average early rate of change in discrepancy for a random sample (n = 41).
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Figure 4. Change in early alliance discrepancy as a predictor of subsequent worry change across
the second half of treatment.
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Figure 5. Change in early alliance discrepancy as a predictor of general distress change across
the second half of treatment.
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Figure 6. Interactive effect of early alliance convergence and patient session 1 alliance on
subsequent general distress change.
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Figure 7. Differences between patient-therapist session progress scores across treatment.
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Figure 8. Panel A shows the average change in session progress discrepancy from session 2 through 14 and Panel B depicts the
variability around the average rate of change in discrepancy for a random sample (n = 41).
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Figure 9. Panel A shows the average change in session progress discrepancy from session 2 through 5 and Panel B depicts the
variability around the average rate of change in discrepancy for a random sample (n = 41).
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Figure 10. Change in early session progress discrepancy as a predictor of subsequent
worry change.
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Figure 11. Session progress discrepancy change from session 2 through 5 as a predictor
of subsequent distress reduction.
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Figure 12. Interactive effect of early session progress convergence/divergence and patient
session 1 progress on subsequent general distress change.
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